雷公藤多甙纳米乳透皮给药系统的研究
|
摘要
目的:利用纳米技术,以增强雷公藤多甙药效、降低其毒副作用为主体思路,制备高效低毒的雷公藤多甙纳米乳透皮制剂,并综合运用动物疾病模型、细胞生物学实验以及家兔体内药物代谢动力学实验对该新制剂的稳定性、安全性、有效性以及体内外释药性能进行深入研究。
内容与方法:(1)雷公藤多甙纳米乳的制备及质量评价建立用于雷公藤多甙纳米乳含量检测的高效液相检测方法。在处方前研究中,测定雷公藤多甙在几种油和表面活性剂中的溶解度,滴定法绘制伪三元相图。根据相图中纳米乳区的大小、纳米乳的稳定性以及药物在油及表面活性剂中的溶解度,筛选最佳处方,制备雷公藤多甙纳米乳。利用染色法判断纳米乳的类型,利用透射电镜、激光粒度分析仪、黏度计、折光仪和电导仪对其进行质量评价,并对其稳定性进行考察。(2)雷公藤多甙纳米乳的安全性评价利用简化寇氏法对雷公藤多甙纳米乳的经口半数致死量进行测定,并对其皮肤急性毒性、皮肤和眼部刺激性进行考察。(3)雷公藤多甙纳米乳的药效学研究建立二甲苯诱导的小鼠急性耳肿胀和以血管通透性为主要改变的急性炎症模型,考察雷公藤多甙纳米乳的抗炎作用;通过醋酸致小鼠扭体试验和热板试验,研究雷公藤多甙纳米乳的镇痛作用;建立大鼠蛋清性关节炎和佐剂型关节炎模型,对雷公藤多甙纳米乳的抗炎及免疫效果进行深入研究;另外,体外培养家兔滑膜细胞,研究雷公藤多甙纳米乳对滑膜细胞的诱导凋亡作用。(4)雷公藤多甙纳米乳对肝、肾的毒性研究肝、肾是雷公藤多甙的主要毒性作用器官。在确定了该药物的药效基础上,我们对其毒副作用是否降低进行研究。首先观察了动物肝肾的组织病理学变化,并检测血清中AST、ALT、BUN以及尿液中尿蛋白的含量变化。另外,体外培养大鼠肝、肾细胞,从细胞水平考察该纳米乳的肝肾毒性。(5)雷公藤多甙纳米乳的体外释药与药动学研究建立血浆中雷公藤多甙纳米乳的含量检测方法。利用显色法进行雷公藤多甙的含量测定,对雷公藤多甙纳米乳的透皮性能进行研究,比较添加氮酮对透皮性能的影响,另外与雷公藤多甙混悬液的透皮性能以及雷公藤多甙片在模拟胃环境中的体外释药性能进行比较;家兔体外涂抹雷公藤多甙纳米乳和灌胃雷公藤多甙片混悬液后,用高效液相色谱测定血浆中药物含量,利用残数法拟合该纳米乳药物与传统剂型在家兔体内的动力学方程,并对其动力学参数进行比较分析。
结果:(1)雷公藤多甙纳米乳的制备及质量评价结果建立了高效液相色谱检测方法,该方法稳定,在125~2000 ng/mL范围内线性关系良好,平均回收率为92.14%。综合纳米乳区大小及溶解度测定结果,最终配方选择以聚氧乙烯氢化蓖麻油为表面活性剂,肉豆蔻酸异丙酯为油相,聚氧乙烯氢化蓖麻油:肉豆蔻酸异丙酯:水的质量比为27: 3.3:69.7,其中可添加5%以下的氮酮;制备的雷公藤多甙纳米乳为澄清、透明、流动性良好的棕黄色液体;亚甲基蓝在其中的扩散速度大于苏丹红Ⅲ,为O/W型纳米乳。经考察,此纳米乳粒子呈圆球形,分散性良好,平均粒径为23.6 nm,Zeta电位为(–5.35±0.42)mV,折光率为(1.3617±0.0051)nD~(20),电导率为(97.6±3.6)μs/cm,黏度为(3.56±0.12)mm~2·s~(-1);且该纳米乳稳定性参数的平均值为3.13%;室温、40℃环境下放置的样品颜色基本不变;在室温环境下放置9个月,样品含量无明显变化。(2)雷公藤多甙纳米乳的安全性评价结果经简化寇氏法计算雷公藤多甙纳米乳的经口半数致死量为977.24 mg/kg,是雷公藤多甙原料药的3.02倍;所制备的雷公藤多甙纳米乳无皮肤急性毒性;无论是单次还是多次给药,对完整皮肤和破损皮肤均无刺激性,对眼无刺激性。(3)雷公藤多甙纳米乳的药效学研究结果所制备的雷公藤多甙纳米乳可以显著抑制二甲苯所致的耳肿胀并降低毛细血管通透性(P<0.01),可以减少醋酸所致的小鼠扭体次数,延长热板痛阈时间(P<0.05)。雷公藤多甙纳米乳对蛋清性关节炎的足肿胀具有保护作用,且表现出一定的缓释性;对佐剂型关节炎大鼠原发侧和继发侧足肿胀有明显的抑制作用;可以增强体内炎症因子SOD的活力、提高NO的含量;从脾淋巴细胞增殖试验可以看出,雷公藤多甙片和雷公藤多甙纳米乳对T、B淋巴细胞增殖抑制率分别为15.2%、25.3%和15.8%、22.9%,抑制率相差分别为10.1%和7.1%;雷公藤多甙纳米乳和雷公藤多甙片可以诱导体外培养的滑膜细胞发生凋亡,流式细胞仪结果显示,同等剂量下前者是后者的3.35倍。(4)雷公藤多甙纳米乳对肝、肾的毒性研究结果组织病理学观察发现相同剂量下,雷公藤多甙纳米乳作用组的肝细胞索基本清晰,但肝细胞稍有肿胀,雷公藤多甙片组的大鼠肝细胞索紊乱,肝细胞变形,有的呈空泡状;雷公藤多甙纳米乳组的大鼠肾小管细胞轻微肿胀,雷公藤多甙片组大鼠肾小管上皮增厚,细胞肿胀、脱落,炎性细胞浸润。雷公藤多甙纳米乳组血清中ALT、AST、BUN和尿液中尿蛋白的含量明显低于雷公藤多甙片组(P<0.05);雷公藤多甙纳米乳对肝细胞的IC50为128.82 mg/mL,是雷公藤多甙片的2.65倍。雷公藤多甙纳米乳对肾细胞的IC50为61.66 mg/mL,是雷公藤多甙片的3.16倍。(5)雷公藤多甙纳米乳体外释药与药动学研究结果建立了血浆中雷公藤内酯甲的含量测定方法,该方法稳定,在62.5~1500 ng/mL线性关系良好,平均回收率为95.41%,可以满足动力学研究需要。通过体外释药性能的研究,雷公藤多甙纳米乳中不含氮酮时稳态渗透速率为75.48μg·cm- 2·h- 1,而当氮酮的含量增加至5%时,稳态渗透速率下降至24.33μg·cm- 2·h- 1,仅是无氮酮配方的32.23%;雷公藤多甙混悬液和雷公藤多甙片透析的稳态渗透速率分别为16.40μg·cm- 2·h- 1和16.15μg·cm- 2·h- 1。通过药动学研究,雷公藤多甙纳米乳透皮给药与雷公藤多甙片口服给药均属于有吸收的二室模型。雷公藤多甙纳米乳的消除半衰期t1/2β为16.956 h,是片剂的1.782倍;雷公藤多甙纳米乳的相对生物利用度是雷公藤多甙片的141.352%,提高了41.35%。
结论:制备的雷公藤多甙纳米乳是澄清、透明、流动性良好的棕黄色液体。该纳米乳属于O/W型,粒子形态大多为圆球形,分散性良好,粒径约为23.6 nm,具有良好的稳定性。该纳米乳的半数致死量显著小于雷公藤多甙片,无皮肤急性毒性,无皮肤刺激性和眼部刺激性,具有安全性。该纳米乳具有显著的抗炎和免疫抑制效果,对体外培养的滑膜细胞有较强的诱导凋亡作用。对肝、肾组织以及对肝、肾细胞的毒性显著降低,临床用药安全。在家兔体内的消除半衰期明显长于传统制剂雷公藤多甙片,相对生物利用度提高。
雷公藤多甙纳米乳具有高效、低毒的优点,并且具有一定的缓释效应,且雷公藤多甙纳米乳制剂已申请国家发明专利,专利申请号:200610104979.2。
Subject: Using the nanotechnology, prepare the nanoemulsion of tripterygium wilfordii polyglycoside in order to strengthen the drug action and degrade the adverse reaction. Study the stability, safety, efficacy and the pharmacokinetics and in vitro release of this praeparatum through animal disease model, cytobiology experiment and pharmacokinetic experiment in rabbit.
Method: (1) The preparation and quality on the tripterygium wilfordii polyglycoside nanoemulsion. To establish the HPLC analytical method for content determine of tripterygium wilfordii polyglycoside nanoemulsion. Preformulation study, determine the dissolubility of tripterygium wilfordii polyglycoside in different oil and surfactant. Draw the three initiatives phase diagram titration. The prescription was screened according to the size of nanoemulsion district and the dissolubility and then the tripterygium wilfordii polyglycoside nanoemulsion was prepared. Judge the type of nanoemulsion using staining method. The quality was evaluated using transmission electron microscope, laser particle size analysis, particle size analysis, refractometer and conductimeter. The stability was investigated. (2) The safety evaluation on tripterygium wilfordii polyglycoside nanoemulsion. Evaluate the safety by acute toxicity (simplify Karber's method), skin acute toxicity, skin irritation and eye irritation (single and several). (3) The pharmacodynamics evaluation on tripterygium wilfordii polyglycoside nanoemulsion. Investigate the anti-inflammatory action through acute inflammation model including acute swelling of ear induced by dimethyl benzene and the changes of vasopermeability. Investigate the analgesic effect through mouse writhing test and hot plate test. Study the anti-inflammatory action and immunization action through the model of albumen arthritis and adjuvant arthritis. Otherwise, in vitro culture the rabbit synoviocyte, study the enhancement Apoptosis action of tripterygium wilfordii polyglycoside nanoemulsion. (4) Toxicity on liver and kidney of tripterygium wilfordii polyglycoside nanoemulsion. First, observe the histopathological change of liver and kidney and detect the content of AST、ALT、BUN in serum and the content of Urine protein in urine. Second, study the cytotoxicity through in vitro culture the hepatocyte and renal tubular epithelial cell. (5) The pharmacokinetics and in vitro release of tripterygium wilfordii polyglycoside nanoemulsion. To establish the HPLC analytical method was used in dynamic. Study the penetrate efficiency, researched the influence of adding azone in prescription and the release behavior difference between the prescription, suspl of tripterygium wilfordii polyglycoside and tripterygium wilfordii polyglycoside tablets. After painting the tripterygium wilfordii polyglycoside nanoemulsion and intragastric administration tripterygium wilfordii polyglycoside tablets in rabbits, determine the content of wilforlide A in blood plasma. Using method of residual fitting the kinetic equation and then calculate the parameter of dynamics. So study the differences between nanoemulsion and tablets.
Results: (1) The results of preparation and quality on tripterygium wilfordii polyglycoside nanoemulsion. The HPLC analytical method for content determine of wilforlide A was stabilize. The good line range was 125~1500 ng/mL. The mean recovery was 92.14%, it could be used in quality control research. According to the size of nanoemulsion district and the dissolubility, RH-40 and IPM were choosed the surfactant and the oil phase of the optimization prescription. And the proportion by weight of RH-40, IPM and water was 27: 3.3:69.7. Content of azone in prescription should lower 5%. tripterygium wilfordii polyglycoside nanoemulsion was a kind of clear, transparent, satis flowability buffy liquid. Spreading rate of methane blue was higher than the Sudan redⅢ. So the nanoemulsion was assessed O/W form. The nanoemulsion particle was globular, satis dispersibility, the mean diameter was 23.6 nm, Zeta electric potential was (–5.35±0.42) mV, refractive index was (1.3617±0.0051) nD~(20), conductivity was (97.6±3.6)μs/cm, viscosity was (3.56±0.12) mm~2·s~(-1), stability parameter was 3.13%. The color of nanoemulsion was invariably in room temperature and 40℃, the content of nanoemulsion was invariably in room temperature in nine months. (2) The results of safety evaluation on tripterygium wilfordii polyglycoside nanoemulsion. The median lethal dose of tripterygium wilfordii polyglycoside nanoemulsion was 977.24 mg/kg, this was 3.02 times of tripterygium wilfordii polyglycoside crude drug. tripterygium wilfordii polyglycoside nanoemulsion was no skin acute toxicity; there were no stimulation to the party of rabbit’s skin and eye no matter single or multiple dosing. (3) The results of pharmacodynamics evaluation on tripterygium wilfordii polyglycoside nanoemulsion. It could striking inhibit acute swelling of ear induced by dimethyl benzene and degrade the vasopermeability (P<0.01). It could decrease the writhing times and lengthen the time of pain threshold (P<0.05). It could protect the feet swell of albumen arthritis mouse and show the delayed release character. Conspicuous depressant effect to feet swell of adjuvant arthritis were found both primarily side and opposite side. It could reinforce the energy of SOD, increase the content of NO. Inhibition ratio to T、B lymphocyte of tripterygium wilfordii polyglycoside tablets and tripterygium wilfordii polyglycoside nanoemulsion were 15.2%、25.3% and 15.8%、22.9%, the differences were 10.1%and 7.1% respective. It could enhance the apoptosis action of in vitro culture the rabbit synoviocyte. According to the result of flow cytometry, the former was 3.35 times to the latter. (4) The results of toxicity on liver and kidney. In the same dosage, the liver cell cord was clear, the hepatocyte and renal tubular cell were slightly swell in tripterygium wilfordii polyglycoside nanoemulsion group; moreover the liver cell cord was chaotic and the hepatocyte cytomorphosis, sometimes the hepatocyte showed vacuole, the nephric tubule endepiderm is become thickening, cellular swelling, even shedding and inflammatory cell infiltrate in tripterygium wilfordii polyglycoside tablets. The content of ALT、AST、BUN in serum and urine protein in tripterygium wilfordii polyglycoside nanoemulsion group were obviously lower than the group of tripterygium wilfordii polyglycoside tablets (P<0.05). tripterygium wilfordii polyglycoside nanoemulsion’s IC50 was 128.82 mg/mL to hepatocyte, it was 2.65 times to tripterygium wilfordii polyglycoside tablets. tripterygium wilfordii polyglycoside nanoemulsion’s IC50 was 61.66 mg/mL to renal cell, it was 3.16 times to tripterygium wilfordii polyglycoside tablets. (5) The results of pharmacokinetics and in vitro release of tripterygium wilfordii polyglycoside nanoemulsion. The HPLC analytical method for content determine in plasma of wilforlide A was stabilize. The good line range was 62.5~1500 ng/mL. The mean recovery was 95.41%, it could be used in dynamics research. Homeostasis permeate velocity was 75.48μg·cm- 2·h- 1when there were no azone in prescription. Homeostasis permeate velocity was 24.33μg·cm- 2·h- 1when there were 5% azone in prescription, this was 32.23% of former. Homeostasis permeate velocity of the crude drug and the tripterygium wilfordii polyglycoside tablets were 16.40μg·cm- 2·h- 1 and 16.15μg·cm- 2·h- 1. tripterygium wilfordii polyglycoside nanoemulsion and tripterygium wilfordii polyglycoside tablets were all fit for the two room open model. Elimination half life of tripterygium wilfordii polyglycoside nanoemulsion was 16.956 h, it was 1.782 times to tripterygium wilfordii polyglycoside tablets. tripterygium wilfordii polyglycoside nanoemulsion raised relative bioavailability to 141.35%. It was an increase of 41.35% over tripterygium wilfordii polyglycoside tablets.
Conclude: tripterygium wilfordii polyglycoside nanoemulsion is a kind of clear, transparent, satis flowability buffy liquid. It is assessed O/W form. The particle is globular, satis dispersibility, the mean diameter was 23.6 nm. The nanoeulsion have satisfactory stability. The median lethal dose of tripterygium wilfordii polyglycoside nanoemulsion is significant lower than tablets. There is no skin acute toxicity; no stimulation to the party of rabbit’s skin and eye no matter single or multiple dosing. Tripterygium wilfordii polyglycoside nanoemulsion has noticeable anti-inflammatory and immune suppression effect and it can enhance the apoptosis action of in vitro culture the rabbit synoviocyte. Toxicity to liver, kidney, hepatocyte and renal tubular epithelial cell are lower than tablets. So the tripterygium wilfordii polyglycoside nanoemulsion is safety. Elimination half life of tripterygium wilfordii polyglycoside nanoemulsion is longer than the tablets, in addition, relative bioavailability is raised than tablets. High performance, low toxical and delayed release are the character of tripterygium wilfordii polyglycoside nanoemulsion.
The research outcome has been applied for Nation invention patent, apply order is 200610104979.2.
内容与方法:(1)雷公藤多甙纳米乳的制备及质量评价建立用于雷公藤多甙纳米乳含量检测的高效液相检测方法。在处方前研究中,测定雷公藤多甙在几种油和表面活性剂中的溶解度,滴定法绘制伪三元相图。根据相图中纳米乳区的大小、纳米乳的稳定性以及药物在油及表面活性剂中的溶解度,筛选最佳处方,制备雷公藤多甙纳米乳。利用染色法判断纳米乳的类型,利用透射电镜、激光粒度分析仪、黏度计、折光仪和电导仪对其进行质量评价,并对其稳定性进行考察。(2)雷公藤多甙纳米乳的安全性评价利用简化寇氏法对雷公藤多甙纳米乳的经口半数致死量进行测定,并对其皮肤急性毒性、皮肤和眼部刺激性进行考察。(3)雷公藤多甙纳米乳的药效学研究建立二甲苯诱导的小鼠急性耳肿胀和以血管通透性为主要改变的急性炎症模型,考察雷公藤多甙纳米乳的抗炎作用;通过醋酸致小鼠扭体试验和热板试验,研究雷公藤多甙纳米乳的镇痛作用;建立大鼠蛋清性关节炎和佐剂型关节炎模型,对雷公藤多甙纳米乳的抗炎及免疫效果进行深入研究;另外,体外培养家兔滑膜细胞,研究雷公藤多甙纳米乳对滑膜细胞的诱导凋亡作用。(4)雷公藤多甙纳米乳对肝、肾的毒性研究肝、肾是雷公藤多甙的主要毒性作用器官。在确定了该药物的药效基础上,我们对其毒副作用是否降低进行研究。首先观察了动物肝肾的组织病理学变化,并检测血清中AST、ALT、BUN以及尿液中尿蛋白的含量变化。另外,体外培养大鼠肝、肾细胞,从细胞水平考察该纳米乳的肝肾毒性。(5)雷公藤多甙纳米乳的体外释药与药动学研究建立血浆中雷公藤多甙纳米乳的含量检测方法。利用显色法进行雷公藤多甙的含量测定,对雷公藤多甙纳米乳的透皮性能进行研究,比较添加氮酮对透皮性能的影响,另外与雷公藤多甙混悬液的透皮性能以及雷公藤多甙片在模拟胃环境中的体外释药性能进行比较;家兔体外涂抹雷公藤多甙纳米乳和灌胃雷公藤多甙片混悬液后,用高效液相色谱测定血浆中药物含量,利用残数法拟合该纳米乳药物与传统剂型在家兔体内的动力学方程,并对其动力学参数进行比较分析。
结果:(1)雷公藤多甙纳米乳的制备及质量评价结果建立了高效液相色谱检测方法,该方法稳定,在125~2000 ng/mL范围内线性关系良好,平均回收率为92.14%。综合纳米乳区大小及溶解度测定结果,最终配方选择以聚氧乙烯氢化蓖麻油为表面活性剂,肉豆蔻酸异丙酯为油相,聚氧乙烯氢化蓖麻油:肉豆蔻酸异丙酯:水的质量比为27: 3.3:69.7,其中可添加5%以下的氮酮;制备的雷公藤多甙纳米乳为澄清、透明、流动性良好的棕黄色液体;亚甲基蓝在其中的扩散速度大于苏丹红Ⅲ,为O/W型纳米乳。经考察,此纳米乳粒子呈圆球形,分散性良好,平均粒径为23.6 nm,Zeta电位为(–5.35±0.42)mV,折光率为(1.3617±0.0051)nD~(20),电导率为(97.6±3.6)μs/cm,黏度为(3.56±0.12)mm~2·s~(-1);且该纳米乳稳定性参数的平均值为3.13%;室温、40℃环境下放置的样品颜色基本不变;在室温环境下放置9个月,样品含量无明显变化。(2)雷公藤多甙纳米乳的安全性评价结果经简化寇氏法计算雷公藤多甙纳米乳的经口半数致死量为977.24 mg/kg,是雷公藤多甙原料药的3.02倍;所制备的雷公藤多甙纳米乳无皮肤急性毒性;无论是单次还是多次给药,对完整皮肤和破损皮肤均无刺激性,对眼无刺激性。(3)雷公藤多甙纳米乳的药效学研究结果所制备的雷公藤多甙纳米乳可以显著抑制二甲苯所致的耳肿胀并降低毛细血管通透性(P<0.01),可以减少醋酸所致的小鼠扭体次数,延长热板痛阈时间(P<0.05)。雷公藤多甙纳米乳对蛋清性关节炎的足肿胀具有保护作用,且表现出一定的缓释性;对佐剂型关节炎大鼠原发侧和继发侧足肿胀有明显的抑制作用;可以增强体内炎症因子SOD的活力、提高NO的含量;从脾淋巴细胞增殖试验可以看出,雷公藤多甙片和雷公藤多甙纳米乳对T、B淋巴细胞增殖抑制率分别为15.2%、25.3%和15.8%、22.9%,抑制率相差分别为10.1%和7.1%;雷公藤多甙纳米乳和雷公藤多甙片可以诱导体外培养的滑膜细胞发生凋亡,流式细胞仪结果显示,同等剂量下前者是后者的3.35倍。(4)雷公藤多甙纳米乳对肝、肾的毒性研究结果组织病理学观察发现相同剂量下,雷公藤多甙纳米乳作用组的肝细胞索基本清晰,但肝细胞稍有肿胀,雷公藤多甙片组的大鼠肝细胞索紊乱,肝细胞变形,有的呈空泡状;雷公藤多甙纳米乳组的大鼠肾小管细胞轻微肿胀,雷公藤多甙片组大鼠肾小管上皮增厚,细胞肿胀、脱落,炎性细胞浸润。雷公藤多甙纳米乳组血清中ALT、AST、BUN和尿液中尿蛋白的含量明显低于雷公藤多甙片组(P<0.05);雷公藤多甙纳米乳对肝细胞的IC50为128.82 mg/mL,是雷公藤多甙片的2.65倍。雷公藤多甙纳米乳对肾细胞的IC50为61.66 mg/mL,是雷公藤多甙片的3.16倍。(5)雷公藤多甙纳米乳体外释药与药动学研究结果建立了血浆中雷公藤内酯甲的含量测定方法,该方法稳定,在62.5~1500 ng/mL线性关系良好,平均回收率为95.41%,可以满足动力学研究需要。通过体外释药性能的研究,雷公藤多甙纳米乳中不含氮酮时稳态渗透速率为75.48μg·cm- 2·h- 1,而当氮酮的含量增加至5%时,稳态渗透速率下降至24.33μg·cm- 2·h- 1,仅是无氮酮配方的32.23%;雷公藤多甙混悬液和雷公藤多甙片透析的稳态渗透速率分别为16.40μg·cm- 2·h- 1和16.15μg·cm- 2·h- 1。通过药动学研究,雷公藤多甙纳米乳透皮给药与雷公藤多甙片口服给药均属于有吸收的二室模型。雷公藤多甙纳米乳的消除半衰期t1/2β为16.956 h,是片剂的1.782倍;雷公藤多甙纳米乳的相对生物利用度是雷公藤多甙片的141.352%,提高了41.35%。
结论:制备的雷公藤多甙纳米乳是澄清、透明、流动性良好的棕黄色液体。该纳米乳属于O/W型,粒子形态大多为圆球形,分散性良好,粒径约为23.6 nm,具有良好的稳定性。该纳米乳的半数致死量显著小于雷公藤多甙片,无皮肤急性毒性,无皮肤刺激性和眼部刺激性,具有安全性。该纳米乳具有显著的抗炎和免疫抑制效果,对体外培养的滑膜细胞有较强的诱导凋亡作用。对肝、肾组织以及对肝、肾细胞的毒性显著降低,临床用药安全。在家兔体内的消除半衰期明显长于传统制剂雷公藤多甙片,相对生物利用度提高。
雷公藤多甙纳米乳具有高效、低毒的优点,并且具有一定的缓释效应,且雷公藤多甙纳米乳制剂已申请国家发明专利,专利申请号:200610104979.2。
Subject: Using the nanotechnology, prepare the nanoemulsion of tripterygium wilfordii polyglycoside in order to strengthen the drug action and degrade the adverse reaction. Study the stability, safety, efficacy and the pharmacokinetics and in vitro release of this praeparatum through animal disease model, cytobiology experiment and pharmacokinetic experiment in rabbit.
Method: (1) The preparation and quality on the tripterygium wilfordii polyglycoside nanoemulsion. To establish the HPLC analytical method for content determine of tripterygium wilfordii polyglycoside nanoemulsion. Preformulation study, determine the dissolubility of tripterygium wilfordii polyglycoside in different oil and surfactant. Draw the three initiatives phase diagram titration. The prescription was screened according to the size of nanoemulsion district and the dissolubility and then the tripterygium wilfordii polyglycoside nanoemulsion was prepared. Judge the type of nanoemulsion using staining method. The quality was evaluated using transmission electron microscope, laser particle size analysis, particle size analysis, refractometer and conductimeter. The stability was investigated. (2) The safety evaluation on tripterygium wilfordii polyglycoside nanoemulsion. Evaluate the safety by acute toxicity (simplify Karber's method), skin acute toxicity, skin irritation and eye irritation (single and several). (3) The pharmacodynamics evaluation on tripterygium wilfordii polyglycoside nanoemulsion. Investigate the anti-inflammatory action through acute inflammation model including acute swelling of ear induced by dimethyl benzene and the changes of vasopermeability. Investigate the analgesic effect through mouse writhing test and hot plate test. Study the anti-inflammatory action and immunization action through the model of albumen arthritis and adjuvant arthritis. Otherwise, in vitro culture the rabbit synoviocyte, study the enhancement Apoptosis action of tripterygium wilfordii polyglycoside nanoemulsion. (4) Toxicity on liver and kidney of tripterygium wilfordii polyglycoside nanoemulsion. First, observe the histopathological change of liver and kidney and detect the content of AST、ALT、BUN in serum and the content of Urine protein in urine. Second, study the cytotoxicity through in vitro culture the hepatocyte and renal tubular epithelial cell. (5) The pharmacokinetics and in vitro release of tripterygium wilfordii polyglycoside nanoemulsion. To establish the HPLC analytical method was used in dynamic. Study the penetrate efficiency, researched the influence of adding azone in prescription and the release behavior difference between the prescription, suspl of tripterygium wilfordii polyglycoside and tripterygium wilfordii polyglycoside tablets. After painting the tripterygium wilfordii polyglycoside nanoemulsion and intragastric administration tripterygium wilfordii polyglycoside tablets in rabbits, determine the content of wilforlide A in blood plasma. Using method of residual fitting the kinetic equation and then calculate the parameter of dynamics. So study the differences between nanoemulsion and tablets.
Results: (1) The results of preparation and quality on tripterygium wilfordii polyglycoside nanoemulsion. The HPLC analytical method for content determine of wilforlide A was stabilize. The good line range was 125~1500 ng/mL. The mean recovery was 92.14%, it could be used in quality control research. According to the size of nanoemulsion district and the dissolubility, RH-40 and IPM were choosed the surfactant and the oil phase of the optimization prescription. And the proportion by weight of RH-40, IPM and water was 27: 3.3:69.7. Content of azone in prescription should lower 5%. tripterygium wilfordii polyglycoside nanoemulsion was a kind of clear, transparent, satis flowability buffy liquid. Spreading rate of methane blue was higher than the Sudan redⅢ. So the nanoemulsion was assessed O/W form. The nanoemulsion particle was globular, satis dispersibility, the mean diameter was 23.6 nm, Zeta electric potential was (–5.35±0.42) mV, refractive index was (1.3617±0.0051) nD~(20), conductivity was (97.6±3.6)μs/cm, viscosity was (3.56±0.12) mm~2·s~(-1), stability parameter was 3.13%. The color of nanoemulsion was invariably in room temperature and 40℃, the content of nanoemulsion was invariably in room temperature in nine months. (2) The results of safety evaluation on tripterygium wilfordii polyglycoside nanoemulsion. The median lethal dose of tripterygium wilfordii polyglycoside nanoemulsion was 977.24 mg/kg, this was 3.02 times of tripterygium wilfordii polyglycoside crude drug. tripterygium wilfordii polyglycoside nanoemulsion was no skin acute toxicity; there were no stimulation to the party of rabbit’s skin and eye no matter single or multiple dosing. (3) The results of pharmacodynamics evaluation on tripterygium wilfordii polyglycoside nanoemulsion. It could striking inhibit acute swelling of ear induced by dimethyl benzene and degrade the vasopermeability (P<0.01). It could decrease the writhing times and lengthen the time of pain threshold (P<0.05). It could protect the feet swell of albumen arthritis mouse and show the delayed release character. Conspicuous depressant effect to feet swell of adjuvant arthritis were found both primarily side and opposite side. It could reinforce the energy of SOD, increase the content of NO. Inhibition ratio to T、B lymphocyte of tripterygium wilfordii polyglycoside tablets and tripterygium wilfordii polyglycoside nanoemulsion were 15.2%、25.3% and 15.8%、22.9%, the differences were 10.1%and 7.1% respective. It could enhance the apoptosis action of in vitro culture the rabbit synoviocyte. According to the result of flow cytometry, the former was 3.35 times to the latter. (4) The results of toxicity on liver and kidney. In the same dosage, the liver cell cord was clear, the hepatocyte and renal tubular cell were slightly swell in tripterygium wilfordii polyglycoside nanoemulsion group; moreover the liver cell cord was chaotic and the hepatocyte cytomorphosis, sometimes the hepatocyte showed vacuole, the nephric tubule endepiderm is become thickening, cellular swelling, even shedding and inflammatory cell infiltrate in tripterygium wilfordii polyglycoside tablets. The content of ALT、AST、BUN in serum and urine protein in tripterygium wilfordii polyglycoside nanoemulsion group were obviously lower than the group of tripterygium wilfordii polyglycoside tablets (P<0.05). tripterygium wilfordii polyglycoside nanoemulsion’s IC50 was 128.82 mg/mL to hepatocyte, it was 2.65 times to tripterygium wilfordii polyglycoside tablets. tripterygium wilfordii polyglycoside nanoemulsion’s IC50 was 61.66 mg/mL to renal cell, it was 3.16 times to tripterygium wilfordii polyglycoside tablets. (5) The results of pharmacokinetics and in vitro release of tripterygium wilfordii polyglycoside nanoemulsion. The HPLC analytical method for content determine in plasma of wilforlide A was stabilize. The good line range was 62.5~1500 ng/mL. The mean recovery was 95.41%, it could be used in dynamics research. Homeostasis permeate velocity was 75.48μg·cm- 2·h- 1when there were no azone in prescription. Homeostasis permeate velocity was 24.33μg·cm- 2·h- 1when there were 5% azone in prescription, this was 32.23% of former. Homeostasis permeate velocity of the crude drug and the tripterygium wilfordii polyglycoside tablets were 16.40μg·cm- 2·h- 1 and 16.15μg·cm- 2·h- 1. tripterygium wilfordii polyglycoside nanoemulsion and tripterygium wilfordii polyglycoside tablets were all fit for the two room open model. Elimination half life of tripterygium wilfordii polyglycoside nanoemulsion was 16.956 h, it was 1.782 times to tripterygium wilfordii polyglycoside tablets. tripterygium wilfordii polyglycoside nanoemulsion raised relative bioavailability to 141.35%. It was an increase of 41.35% over tripterygium wilfordii polyglycoside tablets.
Conclude: tripterygium wilfordii polyglycoside nanoemulsion is a kind of clear, transparent, satis flowability buffy liquid. It is assessed O/W form. The particle is globular, satis dispersibility, the mean diameter was 23.6 nm. The nanoeulsion have satisfactory stability. The median lethal dose of tripterygium wilfordii polyglycoside nanoemulsion is significant lower than tablets. There is no skin acute toxicity; no stimulation to the party of rabbit’s skin and eye no matter single or multiple dosing. Tripterygium wilfordii polyglycoside nanoemulsion has noticeable anti-inflammatory and immune suppression effect and it can enhance the apoptosis action of in vitro culture the rabbit synoviocyte. Toxicity to liver, kidney, hepatocyte and renal tubular epithelial cell are lower than tablets. So the tripterygium wilfordii polyglycoside nanoemulsion is safety. Elimination half life of tripterygium wilfordii polyglycoside nanoemulsion is longer than the tablets, in addition, relative bioavailability is raised than tablets. High performance, low toxical and delayed release are the character of tripterygium wilfordii polyglycoside nanoemulsion.
The research outcome has been applied for Nation invention patent, apply order is 200610104979.2.
引文
[1] Schulman J H , Hoar T P .Transparent Water-in-oil dispersions :the Oleopathic Hydro-Micelle[J]. Nature, 1943, 152:102-103.
[2] SchmalfubU , Neubert R , Wohlrab W. Modification of drug penetration into human skin using microemulsions [J] .J Control Release ,1997, 46(1):279-285.
[3] Krellgaard M, Influence of microemulsion on cutaneous drug delivery[J].Adv Drug Deliv Rev.2002,1:77-98.
[4] LU Y,JI XX,GAO S,et a1.Studies of lidocaine-lecithin micrcemulsion[J].J Pharm practice.2004,22(3):141- 143.
[5]顾惕人.表面化学[M].北京:科学出版社,1999:88-92.
[6] Shinoda K, Araki M, Sadaghiani A, et al.Lecithin-based microemulsion: phase behaviour and microstructure[J]. J Phys Chem,1991,95:989-993.
[7] J.Th.G. Overbeek.Microemulsion, a field at the border between lyophobic and lyophilic colloids[J]. Faraday Disc Chem Soc, 1978,65:7-19.
[8] 王玉强.槲皮素微乳的研究[D].济南:山东大学,2006.
[9] 李玲.表面活性剂与纳米技术[M]. 北京:化学工业出版社,2004.
[10] Waris Noicharoen W, Lansley AB, Law Rence MJ. Nonionic oil-in-water microemusions: the effect of oil type on phase behaviour[J]. Int J Pharm, 2000,198:7-27.
[11] Gao ZhongGao, Choi Hao.Shio. Hee Jong. Phvsicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporine A[J].Int J Pham. 1998,48(161):75-86.
[12] Kraeling ME. Ristschel WA. Development of a colonic release capsule dosage form and absorption of insulin[J]. Methods Find Exp Clin Pharmacol. 1992,14(3):199-209.
[13] BEGONA BRIME. Amphotericia B in-oil-water lecithin based microemulsion: formulation and toxicity evalution[J]. Journal of pharmaceutical Sci.2002,91(4):1178-1185.
[14] Kim C ,Cho Y ,Gao Z .Preparation and evaluation of biphenyl di methyl dicarboxylate microemulsions for oral delivery[J]. J Controll Rel,20 01,70 :149-155
[15] 张莉, 向东, 洪诤,等.肝靶性去甲蟊素微乳的研究[J].药学学报,2004,39(8):650-655.
[16] 姚静, 周建平, 卢韵等. 聚氧乙烯蓖麻油微乳对血脑屏障通透性的影响[J]. 中国药科大学学报, 2005,36(1):27-30.
[17] 张学农, 唐丽华, 严学莹,等. 紫杉醇自乳化的制备及其在大鼠体内的药动学[J]. 中国新药与临床杂志,2005,24(4):294-298.
[18] 丁平田,赵红. 透皮吸收药物载体――传递体[J]. 国外医药――合成药 生化药 制剂分册, 1997,18(1):48-51.
[19] Schmalfub U, Neubert R, Wohlrab W. Modification of drug penetration into human skin using microemulsion[J]. J Control Rel,1997,46:279-285.
[20] 张立超, 胡晋红. 微乳透皮给药系统的研究进展[J].国外医学药学分册,2004,31(1):44-48.
[21] Reeta RG, Swantrant KJ, Manoj V, AOT water-in-oil microemulsion as a penetration enhancer in transderal drug delivery of 5-fluorouracil[J]. Colloids Surf B:Biointerfaces,2005,41:25-32.
[22] 俞媛, 高申, 陈琰等, 盐酸哌甲酯-卵磷脂微乳的制备及其透皮吸收作用[J]. 中国药学杂志,2005,40(11):843-845.
[23] 陈华兵, 翁婷, 常雪灵等. 布洛芬微乳的制备及其透皮吸收[J].中国药学杂志, 2004,39(1):43-45.
[24] 徐岩,陈祖基,宋洁贞等.毛果芸香碱微乳滴眼剂及滴眼液在兔眼房水中的药代动力学研究[J]. 中华眼科杂志,1999,35(6):446-448.
[25] 林艳琼,甘勇,甘莉等. 地塞米松眼用微乳的研究[J].中国药学杂志,2006,41(5):358-362.
[26] Vyas TK, Babbar AK, Sharma RK,et al. Intranasal mucoadhesive microemulsion of clonazepam: Preliminary studies on brain targeting[J].J Pharm Sci,2006,95(3):570-580.
[27] Zhang Q, Jiang X, Jiang W,et al. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain[J].Int J Pharm,2004,275(1-2):85-96.
[28] Li L, Nandi KH. Development of an ethyl laurate-based microemulsion forrapid-onset intranasal delivery of diazepam[J]. Int J Pharm,2002,237(1-2):77-85.
[29] 陆杨燕,周华峰,夏强等.维甲酸固体脂质纳米粒的制备及兔体外透皮研究[J].中国医药工业杂志.2006,37(1):17-19.
[30] 康纯,闻璃毓,朱霞石.微乳增敏分光光度法测定天麻制剂中的微量锌[J].中国药科大学学报,1998,29(6):450-452.
[31] 闻璃毓,康纯.微乳 TLC 同时分离鉴定 2 中成药的多种成分[J], 中成药,2001,23(2):94-96.
[32] Aiken JH, Huie CW, Use of a microemulsion system to incorporate a lipophilic chiral selector in electrokinetic capillary chromatography[J]. Chromatographia, 1993,35(7/8): 448-450.
[33] Juan M. Sanchez, Victoria Salvado. Comparision of micellar and microemulsion electrokinetic chromatography for the analysis of water-and-fat-soluble vitamins[J]. Journal of Chromatography, 2002,950:241-247.
[34] 周国华,罗国安,古卓良. 乙酰螺旋霉素活性成分的分析[J].分析化学,1998,26(2):137.
[35] 洪利娅,郦玲. 纳米乳毛细管电泳分离吉他霉素组分[J]. 药物分析杂质, 2000,20(4):251-254.
[36] 边佳明,赵维娟,许景峰.国外经皮给药系统的研究进展[J]. 中国药房,2005,16(14):1112-1114.
[37] 胡晋红,张立超,朱全刚.我国透皮给药的研究进展[J].解放军药学学报, 2002,18(1):38-41.
[38] 陈丽娟.新型给药系统的研究进展[J].天津药学,2001,13(3):18-20.
[39] 周韶华, 肖小河, 袁海龙,等. 新型给药系统及其在中药制剂中的研究进展[J]. 中国中药杂志, 2003,28(7):589-592.
[40] 叶咏年. 透皮给药近况选述[J]. 天津药学, 2001,13(3):1-3.
[41] 昝佳,蒋国强,陈军.经皮给药系统的研究进展和发展趋势[J].精细化工,2002,19(63):18-20.
[42] 黄复生,贺俊英.脂质体经皮给药研究进展[J].中国现代应用药学杂志,2002,19(6):460-463.
[43] 胡晋红,张立超,朱全刚.我国透皮给药的研究进展[J].解放军药学学报,2002,18(1):38-41.
[44] 曹琴,丁志建,丁雪鹰.非甾体抗炎药透皮给药的研究进展[J].药学实践杂志,2003,21(3):147-149.
[45] 胡新, 焦元元, 陈旭, 等. 有序排列的类脂双层膜外构筑、稳定性与经皮促渗关系[J]. 中南药学,2004,2(2):67-69.
[46] 陈浩凡, 成志毅, 王锦贤. 促进经皮给药方法的研究进展[J]. 广东药学.2000,10(2):1-5.
[47] 张仲源, 徐莉. 透皮药物体内吸收的另一条途径[J]. 中医外治杂志, 2005,14(1):8-9.
[48] 许景峰, 赵维娟, 张梅等. 100 种药物透皮吸收行为的试验研究及经验回归方程的推论[J]. 中国药学杂志.1998,33(2):86-91.
[49] Sui Yi, Nie Zan. Trans-meridional-point therapeutucs and transdermal therapeutic system[J]. Chinesejournal of clinical rehabilitation, 2005,9(7):210-211.
[50] 刘未艾, 叶德宝. 穴位贴敷疗法透皮给药的研究进展[J]. 中医药通报, 2004,3(4):59-62.
[51] 刘祖舜, 周爱玲, 丁裴. 等. 腧穴对药物化学性刺激的反应[J]. 上海针灸杂志, 1996,15(5):33-34.
[52] 董洪涛, 李静. 经络穴位经皮给药系统的机理研究[J]. 甘肃中医, 1999,12(5):58-59.
[53] Singh P,Boniello S,Liu P,et al.transdermal Iontophoretic delivery of methylphenidate HCl in vivo[J].Int J Pharm,1999,178(1):121-128.
[54] Stamatialis DF,Rolevink HM,Koops GH.Delivery of timolol through artificial membranes and pig stratum comeum[J],J Pharm Sci,2003,92(5):1037-1039.
[55] 王浩,侯惠民.电致孔对离体裸鼠皮肤屏障性质的影响[J].中国医院药学杂志,2002,33(3):124-126.
[56] 潘研 , 赵会英 , 郑俊民 . 电致孔和离子导入对胰岛素经皮渗透的促进作用 [J]. 药学学报,2002,37(8):649-652.
[57] 俞媛.盐酸哌甲酯经皮渗透特性及其透皮给药系统的研究[D].上海: 第二军医大学,2004.
[58] Touitou E,Godin B,Weiss C.Enhanced delivery og drugs into and across the skin by ethosomal[J].Drug Dev Res,2000,50(3/4):406-415.
[59] Touitou E,Dayan N, Bergelsion L,et al.Ethosomea-novel vesicular carriera for enhanced delivery:characterization and skin penetration properties[J].J Controlled Release,2000, 65(3):403-418.
[60] Touitou E,Dodin N,et al.Intracellular delivery mediated by an ethosomal carrier[J]. Biomaterials,2001,22(22):3053-3059.
[61] Fang JY,Hong CT,Chiu WT,et al.Effect of liposomes and niosomes on skin permeation of enoxacin[J].Int J Pharm, 2001,219 (1-2):61-72.
[62] Fang JY,Yu SY,Wu PC,et al.In vitro skin permeation of estradiol from various proniosome formulation[J].Int J Pharm,2001,215(1-2):91-99.
[63] Gevc G,Blume G,New,highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, transfersomes[J].Biochim Biophys Acta,2001,1514(2):191-205.
[64] Guo J,Ping Q,Sun G,et al.Lecithin vesicular carriers for transdermal delivery of cyclosporine A[J].int J Pharm,2000,194(2):201-207.
[65] Wu H,Ramachandran C,Weiner ND,et al.Topical trandport of hydrophilic compounds using water-in-oil nanoemulsions[J],Int J Pharm,2001,220(1~2):63-75.
[66] Youenang P,Martin P,de luca M,et al.Transdermal delivery of glucose through hairless rat skin in vitro: effect of multiple and simple emulsions[J].Int J Pharm,1998,171(2):207-215.
[67] Alvarez-Figueroa MJ,Blanco-Mendez J.Transdermal delivery of methotrexate: iontophor- etic delivery from hydrogels and passive delivery from microemulsions[J].Int J Pharm.2001,215(1):57-65.
[68] 朱晓亮,陈志良,曾抗.微乳透皮给药系统的研究现状及展望[J].广东医学,2005,26(4):563-564.
[69] 王晓黎,蒋雪涛.微乳在药剂学上的应用[J].解放军药学学报, 2000,16(2):88-91.
[70]吴顺,李三鸣,赵国斌.微乳及其在药剂学中的应用[J].沈阳药科大学学报,2003,20(5):381-3 85.
[71] Peltola S, Saarinen-savolainen P, Kiesvaara J, et al. Microemulsion for topical delivery of estradiol[J]. Int J Pharm, 2003, 254(2):99-107 .
[72] Kreilgaard M, Pedersen E J, Jaroszewski J W. NMR characterization and transdermar drug delivery potential of microemusion systems[J]. J Control Release, 2000,69(3):421-433.
[73] Wu H W, Ramachandran C, Weiner N D,et al. Topical transport of hydrophilic compounds usingwater-in-oil nanoemulsion[J]. Int J Pharm, 2001,220(1-2):63-75.
[74] Changez M, Varshney M. Aerosol-OT microemulsions as transdermal carriers of tetracaine hydrochloride[J].Drug Dev Ind Pharm, 2000,26(5):507-512.
[75] Cechel GC, Maffei P, Moretti MD, et al. In vitro permeation through porcine buccal mucosa of Salvia desoleana Atzei & Pici essential oil from topical formulation[J].Int J Pharm, 2000,195(1-2):171-177.
[76] Luo Xingping, Zhai Zongde, Zhao Yanfang. Microemulsion electrolinetic chromatographic determination of bufadienolides in toad venom and in traditional Chinese medicine[J]. Anal Bioanal Che m ,2006, 384:1254-1258.
[77] 王丽君,姜晓冬,高霞.雷公藤多甙片的不良反应[J].基层中药杂志.1998,12(4):52-54.
[78] 秦万章.雷公藤抗炎免疫药理[C].第四次全国雷公藤学术会议论文汇编.上海:2004.5:75-80.
[79] 力弘,贾永锋,李端.雷公藤多甙的抗炎和免疫抑制作用[J].上海医科大学学报, 2000,27(6):502-505.
[80] 周朝晖,何守志.雷公藤多甙对人工晶状体表面纤维蛋白膜形成的影响[J].眼科研究,1999,17 (3):177-179.
[81] 张永健,苏素文,谢彦华等.雷公藤多甙的抗炎作用和 NO 的关系[J].中国药学杂志,2000,35(1):20-23.
[82] 丁 育 民 , 张 茂 榉 . 雷 公 藤 多 甙 治 疗 结 缔 组 织 疾 病 的 临 床 研 究 [J]. 甘 肃 中 医 学 院 学报.1998,15(2):21-24.
[83] 张曼华.雷公藤多甙长期间隙治疗类风湿性关节炎 38 例疗效分析[J].苏州医学院学报,1994,14(4):321-322.
[84] 刘晓辉.雷公藤及其制剂治疗类风湿性关节炎的研究进展[G].第四次全国雷公藤学术会议论文汇编 2004.5 上海 98-103.
[85] 刘健,韩明向,张皖东等.新风胶囊对佐剂性关节炎大鼠血清 IL-1、TNF-α、IL-4 和 IL-10 的影响[J].安徽中医学院学报,2002,21(2):44-46.
[86] 于秋艳,张海鹏,包娜仁.雷公藤多甙对 αGVHD 小鼠 T 细胞及相关细胞因子的影响[J].中国病理生理杂志,2001(8):754.
[87] 傅建斌,梁遂兴,任利群等.雷公藤多甙对类风湿性关节炎患者血浆 TNF-α 水平影响的研究[J].中医正骨.2001,13(9):13-14.
[88] 薛建敏,徐永健,张珍祥等.雷公藤内酯醇对致敏大鼠淋巴细胞凋亡的影响[J].中华微生物和免疫学杂志,2001(2):130-133.
[89] 鲍一笑,张璐定,李莉等.雷公藤红素对 HMC-1 细胞凋亡相关基因表达的影响[J].第二军医大学学报,2001,(9):833-835.
[90] 刘健,张皖东,陈光亮等.新风胶囊对佐剂性关节炎大鼠疗效及滑膜 fas、fasL 及 bcl-2 表达的影响[J].中国中西医结合杂志,2002,22(8):599-602.
[91] 王国春 , 吴东海 . 雷公藤对类风湿性关节炎患者淋巴细胞亚群的影响 [J]. 中华内科杂志,1994(1):41-42.
[92] 要庆平,张乃峥.雷公藤单体 T4 对类风湿性关节炎患者及正常人外周血单个核细胞增殖的影响[J].中国医学科学院学报,1994(5):352-355.
[93] 高锦团 . 雷公藤多甙治疗激素依赖型阿司匹林性哮喘 36 例 [J]. 中国中西医结合杂志.199414(12):727-729.
[94] 戴小欣.雷公藤在临床的运用及研究进展[J].湖南中医学院学报,1994(4):58-60.
[95] 訾晓梅,刘青云,彭代银,等.雷公藤贴膏抗炎镇痛作用的实验研究[J].中药新药与临床药理,2001(5):345-347.
[96]杨俊伟,戴春笋,陈朝红,等,雷公藤内酯醇对 T 细胞功能的影响与 Camp/PKA 的关系[J].肾脏病与透析肾移植杂志,1998, 7 (2):106-113.
[97]Yang Y L, Liu Z H, Tolosa E, et al, Triptolide induces apoptotic death of T lymphocyte[J]. Immunopharmacol, 1998, 40:139-149.
[98] Li, Xiao-Yu, Immunomodulating components from Chinese medicines[J], Pharm aceutical biology, (Lisse, Netherlands), 2000. 38(Suppl.)33-40.
[99]董兴刚,史继学.雷公藤多试对肾性蛋自尿患者外周血单个核细胞作用的研究[J].山东医科大学学报,1999,37 (3):207-208.
[100]虞海燕,秦万章,吴厚生.雷公藤治疗系统性红斑狼疮免疫机制的研究[J].中国现代应用药学杂志,1999 ,16(2):10-13.
[101] 王振刚,王芳.雷公藤多甙诱导类风湿关节炎患者外周血单个核细胞的凋亡[J].中华风湿病学杂志,2001,5(5):325-326.
[102] Utz pj, Anderson P, Posttranslational Protein modification, apoptosis, and the bypass of tolerance to autoantigen[J].Arthritis Rheum,1998, 41:1152-1160.
[103] Lin KX, Wang CZ, Qian GS, et al, T Wilfordii hook F. inhibits expressions of IL-5 and GM-CSF by suppression activator protein-1 activites[J].Chin J Im munol, 2000,15:325-328.
[104] 朱学军,刘志红.雷公藤内酯醇对人树突状细胞体外发育及免疫学功能的影响[J].肾脏病与透析肾移植杂志,2001,10(3):217-222.
[105] 王胜军,姚笙,谢芳艺等.雷公藤多甙和白细胞介素-10 对人树突状细胞表面人类白细胞抗原-DR和 CD80 表达及白细胞介素-12p40 转录和分泌的影响[J].南京医科大学学报,2001, 21 (1):1-5.
[106] 王长征,王春霞,金远林等.哮喘豚鼠 IL-5、IL-3、GM-CSF mRNA 表达及雷公藤内酯的影响[J].中华微生物和免疫学杂志,1998,18 (2):145-148.
[107] 赖克方,王长征,郭小明等.雷公藤甲素抑制 IL-5 介导的人嗜酸性粒细胞存活延长作用及其机制研究[J].中国免疫学杂志,2000,16(11):601-603, 606.
[108] 王长征,王金平,周泽云等.雷公藤多甙治疗慢性重度哮喘的临床观察[J].实用肺科杂志,1998, 5 (1):17.
[109] 刘浩,刘志红.雷公藤内酯醇对 T 淋巴细胞核因子-κB 及其抑制分子的影响[J].南京大学学报:自科版,2000,36(5):603-609.
[110] 王军,王鹏志.CD23 在小鼠小肠移植排斥反应中作用的研究[J].天津医药.1999, 27(12):739-741.
[111] 张兴义,孙梅,王荣有.雷公藤多甙对家兔移植心脏免疫损伤性冠状动脉硬化的影响[J].白求恩医科大学学报,2000,26(1):13-14.
[112]张业伟,钱海鑫,薛换洲等.雷公藤多甙在器官移植中的应用机制 [J].中国中西医结合外科杂志,2005,11 (1):86 -88.
[113]罗佳波,李吉来,贺丰等.雷公藤在移植免疫中的研究与应用概况[J].中国中医基础医学杂志,2000,6 (2):59 -63.
[114] 高小平,李伯刚,周建等.雷公藤内酯醇体外抗肿瘤作用和诱导细胞凋亡的研究[J].天然产物研究与开发,2000,12(1):18-21.
[115] Jiang, Xiao-IIua, Wong, Benjamin Chun-Yu, et al, Functional p53 is required for triptolide-induced apotosis and AP-1 and nuclear factor-κB activation in gastric cancer cells[J]. Oncogene, 20(55):8009-8018.
[116] 周幽心,黄煌伦,许期年等.雷公藤单体体外抑制胶质瘤细胞的实验研究[J].癌症杂志,2002, 21(10):1106-1108.
[117] Lee KY, Chang W, Qiu D, et al, PG490(triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells[J].Journal of Biology Chemistry, 1999,274(19):13451-13455.
[118] 夏焱,段宏泉,张铁军,等. 雷公藤属药用植物研究进展[J].中草药.2005,36(7):1093-1096.
[119] 马文领, 刘卫.雷公藤及铅,镉对小鼠睾丸间质细胞一氧化氮合酶活性的影响[J].解剖学报.2000,31(2):183-185.
[120] 王岚, 刘惟二. 雷公藤内酯酮的雄性抗生育作用及其作用机制[J].中国医学科学院学报.2000,22(3):224-226.
[121] 夏焱.雷公藤有效成分的含量测定及色谱指纹图谱研究[D]. 天津:天津大学,2005.
[122] 韦登明,黄光照.雷公藤及其单体的药理和毒理病理学研究进展[J].中药材.2003,26 (12):894-897.
[123] 吴达荣, 安爱君, 邓有顺. 雷公藤临床应用的不良反应[J].吉林中医药, 1995,(1):40.
[124] 钱叶勇, 石炳毅, 梁春泉, 等. 雷公藤多甙对肾移植受体生殖器官的影响作用[J],中华泌尿外科杂志,2002,23(4):209-211.
[125] 邵军. 雷公藤多甙片的不良反应[J]. 医药导报. 1996,15(1):41-42.
[126] 周玉芬 , 顾正平 , 浦海英 . 雷公藤多甙片致急性肝功能损伤 1 例 [J]. 中国临床药学杂志,2002(11):5,301.
[127] 李宏,仲跻明,周海洋等.雷公藤多甙治疗肾小球疾病不良反应观察[J].药物不良反应杂志,2000,1:25-27.
[128] 范兴忠,陈勇,李新东.雷公藤在免疫性疾病治疗中副作用的观察[J].中国中西医结合肾病杂志.2001,2(2):83-85.
[129] 刘玉凤,邓惠英.雷公藤多甙致肝损伤的临床报道[J].中医药研究.1997,13(5):20.
[130] 田键,佘振钰,周孝瑚等.雷公藤多甙对大鼠生精细胞及其酶活性的影响[J].生殖与避孕,1993,13(2):127.
[131] 唐永, 张霞, 苏蓓蓓. 雷公藤在皮肤科应用中的不良反应[J]. 临床皮肤科杂志, 1998,27(6):377.
[132] 张维真, 王淑华. 雷公藤、瘤可宁对肾病患儿性腺功能的远期影响[J].中国中西医结合杂志. 1996,16(2):113.
[133] 舒尚义.口服昆明山海棠引起闭经 42 例临床观察[J].昆明医学院学报,1980,3:38.
[134] 丁艳蕊. 雷公藤毒副反应概述[J],中医药研究. 1994,(3):60.
[135] 朱天忠, 几种具有肾毒性的中药[J]. 中华肾脏病杂志,1991,7(3):190.
[136] 黄煌. 雷公藤中毒 31 例临床分析[J]. 中华内科杂志,1982,(6):363.
[137] 王淑芬,刘玉春. 雷公藤肾毒性的临床观察[J].中国中药杂志,1996,21(1):52-54.
[138] 郝向春,口服雷公藤多甙片出现多形性红斑药疹 1 例[J].中国中药杂志,1993,18(3):182.
[139] 曹建国,阮学东.雷公藤多甙片致结节性红斑 1 例[J].中国中药杂志,1994,19(12):759. [140」傅明建, 王月华, 张宝样. 雷公藤糖浆引起皮肤变应性血管炎 1 例[J].临床皮肤科杂志.1993, 22(1):52.
[141] 梅淑艳.长期应用雷公藤治疗类风湿关节炎的不良反应[J].佳木斯医学院学报,1997,20(5): 72.
[142] 巫明植. 雷公藤中毒致心律失常 1 例[J].黑龙江中医药,1994,(5):44.
[143] 陈林囡,蔡辉,于德勇. 雷公藤中毒 10 例临床分析[J].江苏医学,1987,13(2):667.
[144] 邓楚宽,雷公藤致心律失常和心电图改变的临床分析[J].中西医结合杂志,1989,(6):337.
[145] 陆晓和,陈巧云,钟荷娣,等.雷公藤多甙片致急性粒细胞减少症 9 例[J].中国医院药学杂志,1993,13(12):55.
[146] 顾克显,郑家润.雷公藤的药理及毒理研究[J].江苏医药.1987,(12):644.
[147] 陆晓如.雷公藤多甙片致急性粒细胞减少症 9 例[J].中国医院药学杂志,1993,13(2):559.
[148] 吕鹏. 雷公藤中毒原因探讨[J].天津药学,2001,13(6):49-50.
[149] 沈子龙,谢启昆. 雷公藤巴布剂透皮吸收研究[J].中国药科大学学报.1994,25(3):141-144.
[150] 季晖 , 孙备 . 雷公藤巴布剂 对大鼠佐 剂 性关节 炎 的治疗 作 用 [J]. 中 国药科大学 学报.1995,26(4):223-225.
[151] 李瑞林. 雷公藤临床安全合理运用经验[J].中国中西医结合杂志,2002,22(8):567-568.
[152] 戴寿荣,靳晓青,沈越等.滴丸剂对雷公藤减毒增效的试验研究[J],现代中药研究与实践,2003,17(5):32~33.
[153] 国家药典委员会,中华人民共和国 药典 2000 版,北京:中国医药科技出版社,2000.
[154] 部颁中药 17 册 WB3-B-3350-98,雷公藤多甙片质量标准.
[155] 阙慧卿,邓思珊,林绥.雷公藤内酯甲含量测定方法的改进[J].中药材.2005,28(2):144-145.
[156] 谢谊,王实强,刘可柔.反相高效液相色谱法测定雷公藤多甙片中雷公藤酯甲的含量研究[J].湖南中医杂志.2007,23(1):79~80.
[157] 林启寿.中草药化学成分[M].北京:科学出版社,1977.390.
[158] 刘法千,鲍立曾,熊仕强. HPLC 法测定雷公藤多苷中雷公藤内酯甲的含量[J].中国药品标准,2007,8(4):38-40.
[159] 吴晓辉,刘玉玲.微乳作为经皮给药载体的研究进展[J].中国药学杂志. 2006,41(22):1680-1685.
[160] Rong G, Genping S, Weili Y. Enhancing stability of vitamin C in CTAB/n-C5H10OH/H2O system[J]. Chem J Chinese Univer,1997,18(4): 600-604.
[161] Qian W, Hongmei D, Meiyuan ZH. Studies on diagrams of microemusion[J]. Northwest Pharmaceu, 1997,12(2):72-73.
[162] 郭宏.奥沙普秦透皮给药系统的设计与评价[D].辽宁沈阳:沈阳药科大学,2007.
[163] 曹发昊.苦参碱微乳的研究[D].陕西杨凌:西北农林科技大学,2007.
[164] 吴顺芹.氟比洛芬微乳制剂的研究[D].辽宁沈阳: 沈阳药科大学,2004.
[165] 寇贺红.丁香酚纳米乳的研制[D].陕西杨凌:西北农林科技大学,2006.
[166] 朱盛山.药物新剂型[M].北京:化学工业出版社,2003.
[167] Schechter R S. Microemulsion and Related Systems[M].New York: Marcel Dekker,1998,1-200.
[168] 于爱华.葛根素口服微乳制剂的研究[D].山东济南:山东大学,2006.
[169] 杨惊宇.隐丹参酮微乳的制备工艺及相对生物利用度的测定[D].湖南: 湖南中医学院,2005.
[170] 李华.长春西汀透皮给药系统的设计与评价[D].辽宁沈阳:沈阳药科大学,2004.
[171] GB15193.3-94 食品安全性毒理学评价程序与方法.
[172] Cao Z S,Lu F Q, Microemulsion and their apphcation for thednlgs[J].World Pharmacy,1993,14(5):289-293.
[173] 王刚,傅经国,王玉东等.O/W 型微乳的制备及其对皮肤刺激性的检测[J].日用化学工业.2006,36(5):287-290.
[174] 周力国.药物毒理学[M].北京:中国医药科技出版社,2001.9.
[175] 张学梅,廉莲.复方雷公藤多甙的毒性研究[J].辽宁中医杂志.2005,32(7):719-720.
[176] 彭勃,苗明三,王宇亮. 雷公藤多甙片致小鼠急性肝损伤的初步探讨[J]. 中国中药杂志.2003,28(11):1067~1070.
[177] 刘玉凤,邓惠英.雷公藤多甙致肝损伤的临床报道[J].中医药研究.1997,13(5):20.
[178] 李龙. 雷公藤及昆明山海棠引起的肾损害[J].中国临床医生.2006,34(12):9-10.
[179] Lawrence M. J, Drees G. Microemulsion-based media as novel drug delivery systems[J]. Advanced Drug Delivery Reviews, 2000,45(1): 89-121.
[180] 陈华兵,翁 婷, 常雪灵, 等.布洛芬微乳的制备及其透皮吸收研究[J]. 中国药学杂志,2004, 39(1): 43-45.
[181] 宋金春 , 王玉广 . 马钱子碱微乳的制备及其体外透皮吸收的研究 [J]. 中国药学杂志 , 2006,41(12):928-931.
[182] 廉云飞.吲哚美辛微乳经皮制剂的研究[D].南京:中国药科大学,2004.
[183] Mei Z N, Li X K, Wu Q R, et al. The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle[J].Pharmacological research,2005,5 1 :345-351.
[184] 贾公孚, 李涛, 许莉. 药物毒副反应防治手册[M]. 北京:中国协和医科大学出版社, 2004.
[185] 孙红武, 欧阳五庆.盐酸黄连素纳米微乳的研制及其体外抗菌活性研究[J]. 西北农林科技大学学报:自然科学版, 2007,35(1):54-57.
[186] 杨惊宇, 严 冬,罗杰英, 等. 新型药物剂型—微乳[J].中国医学工程.2005,13(4):378-381.
[187] 高 岚, 张仲一, 张莉,等. 薏苡仁汤镇痛消炎作用试验研究[J].天津中医学院学报,2005, 24(1):17-19.
[188] 陈奇主编.中药药理研究方法学[M].北京:人民卫生出版社,1993: 305-307.
[189] 杜冠华,李学军,张永祥,等.药理学实验指南一新药发现和药理学评价[M].北京:科学出版社,2001:529-539.
[190] 章灵华. 丹皮酚抗炎免疫调节作用及其机制[D]. 北京: 中国协和医科大学,1995.
[191] 肖 诚, 何颖辉, 黄芳华,等. 雷公藤多甙对佐剂性关节炎大鼠自由基和炎症因子的影响[J].北京中医药大学学报,2006,29(6):389-392.
[192] 赵 宁, 周 静,肖 诚,等.雷公藤多甙对大鼠佐剂性关节炎黏膜免疫的影响[J].中国中医药信息杂志,2005,12(10):32-33.
[193] 于海荣.目穿山龙总皂甙对大鼠淋巴细胞功能影响的血清药理学研究[D].石家庄:河北药科大学,2004.
[194] 徐红丽,郭婷婷,傅 莉,等.5 种海洋动物多糖对体外小鼠脾淋巴细胞及大鼠睾丸支持细胞增殖作用的比较[J].中国药学杂志, 2006,41(11):839-841.
[195] 邓兆智,林院昌,欧润妹,等.复方雷公藤涂膜剂治疗活动期类风湿关节炎的临床再观察[J].广州中医药大学学报,1998,15,(3):180.
[196] Yu L, Wu S L, Zhang M, et al. Effect of resveratrol alone and its combination with cyclosporine A on the immune function of human peripheral blood Tlymphocytes[J]. Chin J Cell Mol Immunol, 2003,19(6): 549-551.
[197] Anna K, Nissim G. Microemulsions as transdermal drug delivery vehicle[J]. Advances and Interface Science.2006,123-126:369-385.
[198] Rhee Y S, Choi J G, Chi S C, et al. Transdermal delivery of ketoprofen using microemusions[J]. Int J Pharm, 2001,228:161.
[199] 陈纪藩,刘清平,陈光星,等通痹灵对胶原诱导性关节炎大鼠滑膜组织血管内皮生长因子表达水平的影响汇[J].广州中医药大学学报.2003,20(1):4.
[200] 马东来,李俊,陈敏珠.大鼠佐剂型关节炎的诱导激起免疫异常研究[J].中国实验临床免疫学杂志.1995,7(3):1.
[201] 黄世峰,肖长虹,顾为望,等. 兔关节滑膜细胞的分离、培养和纯化[J].中国人兽共患病学报,2006,22(11):1045-1047.
[202] 王斌,陈敏珠,徐叔云.大鼠滑膜细胞的分离和培养[J].中国药理学通报,1994,10(2):73-74.
[203] 唐玲丽, 高洁生, 陈新瑞. 白藜芦醇体外诱导类风湿性关节炎滑膜细胞凋亡的实验研究[J]. 中南药学. 2006,4(4):245-248.
[204] 曾润铭,刘梦璋,林菁.四种常用抗类风湿性药物对成纤维样滑膜细胞体外增殖的影响[J].2005,9(10):67-69.
[205] 窦建卫,雷 莹,王嗣岑. 雷公藤毒性的研究现状[J].陕西中医.2006,27(4):485-487.
[206] 王丽君,姜晓冬.雷公藤多甙片的不良反应[J].基层中药杂志.1998,12(4):52-54.
[207] Kawagoshi Y ,Tsukagoshi Y, Fukunaga L. Determination of estrogenic activity in la ndfill leachate by simplified yeast two-hybrid assay.J Environ Monit.2002,4(6):1040-1046.
[208] 周光伟,沈权,金若钰,等.雷公藤多甙对类风湿性关节炎患者滑膜细胞凋亡的影响[J].浙江临床医学.2007,9(8):1034-1035.
[209] 刘峰,董红宇,董丽华,等. 雷公藤多甙诱导类风湿性关节炎滑膜细胞凋亡的研究[J].吉林医学,2005,26(4):356-357.
[210] 刘玉凤,邓惠英.雷公藤多甙致肝损伤的临床报道[J].中医药研究.1997,13(5):163.
[211] 陈勇, 程明, 刘春霞.肝脏毒性中药的研究现状与展望[J].中草药,2004,35(11):1315-1317.
[212] 李龙.雷公藤及昆明山海棠引起的肾损害[J].中国临床医生.2006,34(12):9-10.
[213] 顾光. 肝、肾毒性体外筛选方法的建立及其在保健食品原料毒性筛选上的应用[D]. 北京: 中国疾病预防控制中心, 2005.
[214] Kawagoshi Y, Tsukagoshi Y, Fukunaga I. Determination of estrogenic activity in landfill leachate by simplified yeast two-hybrid assay. J Environ Monit, 2002,4(6): 1040-1046.
[215] 陈新谦, 金有豫. 新编药物学[M]. 北京:人民卫生出版社. 1975.
[216] 孙洪武.黄连素纳米乳给药系统的研究[D].陕西杨凌:西北农林科技大学,2007.
[217] 聂侃,安伟健,夏光成.不同产地雷公藤属植物根中有效成分含量的比较[J].中草药.199425, (10):539-541.
[218] 中国药典委员会. 中国药典[M]. 北京,2005.
[219] 朱全刚,胡晋红,奚炜,等.酮洛芬前体药物皮肤渗透代谢的立体选择性研究[J].中国药科大学学报.2005,36(1):18-21.
[220] 潘卫三.新药制剂技术[M].北京:化学工业出版社.2004.
[221] 徐叔云,陈修,卞如濂.临床药理学(上)[M].上海:上海科学技术出版社,1983.
[222] 王广基.药物代谢动力学[M].北京:化学工业出版社,2005.
[223] 刘昌孝.实用药物动力学[M].天津:中国医药科技出版社,2003.
[224] 魏树礼.生物药剂学与药物动力学[M]. 北京:中国协和医科大学联合出版社.1997.
[225] 杨惊宇.隐丹参酮微乳的制备工艺及相对生物利用度的测定[D].湖南长沙:湖南中医学院,2005.
[226] 李佩芬,李巧云,李瑞.雷公藤多甙的表观动力学参数测定[J].中药药理与临床.1994(1):29-31.
[2] SchmalfubU , Neubert R , Wohlrab W. Modification of drug penetration into human skin using microemulsions [J] .J Control Release ,1997, 46(1):279-285.
[3] Krellgaard M, Influence of microemulsion on cutaneous drug delivery[J].Adv Drug Deliv Rev.2002,1:77-98.
[4] LU Y,JI XX,GAO S,et a1.Studies of lidocaine-lecithin micrcemulsion[J].J Pharm practice.2004,22(3):141- 143.
[5]顾惕人.表面化学[M].北京:科学出版社,1999:88-92.
[6] Shinoda K, Araki M, Sadaghiani A, et al.Lecithin-based microemulsion: phase behaviour and microstructure[J]. J Phys Chem,1991,95:989-993.
[7] J.Th.G. Overbeek.Microemulsion, a field at the border between lyophobic and lyophilic colloids[J]. Faraday Disc Chem Soc, 1978,65:7-19.
[8] 王玉强.槲皮素微乳的研究[D].济南:山东大学,2006.
[9] 李玲.表面活性剂与纳米技术[M]. 北京:化学工业出版社,2004.
[10] Waris Noicharoen W, Lansley AB, Law Rence MJ. Nonionic oil-in-water microemusions: the effect of oil type on phase behaviour[J]. Int J Pharm, 2000,198:7-27.
[11] Gao ZhongGao, Choi Hao.Shio. Hee Jong. Phvsicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporine A[J].Int J Pham. 1998,48(161):75-86.
[12] Kraeling ME. Ristschel WA. Development of a colonic release capsule dosage form and absorption of insulin[J]. Methods Find Exp Clin Pharmacol. 1992,14(3):199-209.
[13] BEGONA BRIME. Amphotericia B in-oil-water lecithin based microemulsion: formulation and toxicity evalution[J]. Journal of pharmaceutical Sci.2002,91(4):1178-1185.
[14] Kim C ,Cho Y ,Gao Z .Preparation and evaluation of biphenyl di methyl dicarboxylate microemulsions for oral delivery[J]. J Controll Rel,20 01,70 :149-155
[15] 张莉, 向东, 洪诤,等.肝靶性去甲蟊素微乳的研究[J].药学学报,2004,39(8):650-655.
[16] 姚静, 周建平, 卢韵等. 聚氧乙烯蓖麻油微乳对血脑屏障通透性的影响[J]. 中国药科大学学报, 2005,36(1):27-30.
[17] 张学农, 唐丽华, 严学莹,等. 紫杉醇自乳化的制备及其在大鼠体内的药动学[J]. 中国新药与临床杂志,2005,24(4):294-298.
[18] 丁平田,赵红. 透皮吸收药物载体――传递体[J]. 国外医药――合成药 生化药 制剂分册, 1997,18(1):48-51.
[19] Schmalfub U, Neubert R, Wohlrab W. Modification of drug penetration into human skin using microemulsion[J]. J Control Rel,1997,46:279-285.
[20] 张立超, 胡晋红. 微乳透皮给药系统的研究进展[J].国外医学药学分册,2004,31(1):44-48.
[21] Reeta RG, Swantrant KJ, Manoj V, AOT water-in-oil microemulsion as a penetration enhancer in transderal drug delivery of 5-fluorouracil[J]. Colloids Surf B:Biointerfaces,2005,41:25-32.
[22] 俞媛, 高申, 陈琰等, 盐酸哌甲酯-卵磷脂微乳的制备及其透皮吸收作用[J]. 中国药学杂志,2005,40(11):843-845.
[23] 陈华兵, 翁婷, 常雪灵等. 布洛芬微乳的制备及其透皮吸收[J].中国药学杂志, 2004,39(1):43-45.
[24] 徐岩,陈祖基,宋洁贞等.毛果芸香碱微乳滴眼剂及滴眼液在兔眼房水中的药代动力学研究[J]. 中华眼科杂志,1999,35(6):446-448.
[25] 林艳琼,甘勇,甘莉等. 地塞米松眼用微乳的研究[J].中国药学杂志,2006,41(5):358-362.
[26] Vyas TK, Babbar AK, Sharma RK,et al. Intranasal mucoadhesive microemulsion of clonazepam: Preliminary studies on brain targeting[J].J Pharm Sci,2006,95(3):570-580.
[27] Zhang Q, Jiang X, Jiang W,et al. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain[J].Int J Pharm,2004,275(1-2):85-96.
[28] Li L, Nandi KH. Development of an ethyl laurate-based microemulsion forrapid-onset intranasal delivery of diazepam[J]. Int J Pharm,2002,237(1-2):77-85.
[29] 陆杨燕,周华峰,夏强等.维甲酸固体脂质纳米粒的制备及兔体外透皮研究[J].中国医药工业杂志.2006,37(1):17-19.
[30] 康纯,闻璃毓,朱霞石.微乳增敏分光光度法测定天麻制剂中的微量锌[J].中国药科大学学报,1998,29(6):450-452.
[31] 闻璃毓,康纯.微乳 TLC 同时分离鉴定 2 中成药的多种成分[J], 中成药,2001,23(2):94-96.
[32] Aiken JH, Huie CW, Use of a microemulsion system to incorporate a lipophilic chiral selector in electrokinetic capillary chromatography[J]. Chromatographia, 1993,35(7/8): 448-450.
[33] Juan M. Sanchez, Victoria Salvado. Comparision of micellar and microemulsion electrokinetic chromatography for the analysis of water-and-fat-soluble vitamins[J]. Journal of Chromatography, 2002,950:241-247.
[34] 周国华,罗国安,古卓良. 乙酰螺旋霉素活性成分的分析[J].分析化学,1998,26(2):137.
[35] 洪利娅,郦玲. 纳米乳毛细管电泳分离吉他霉素组分[J]. 药物分析杂质, 2000,20(4):251-254.
[36] 边佳明,赵维娟,许景峰.国外经皮给药系统的研究进展[J]. 中国药房,2005,16(14):1112-1114.
[37] 胡晋红,张立超,朱全刚.我国透皮给药的研究进展[J].解放军药学学报, 2002,18(1):38-41.
[38] 陈丽娟.新型给药系统的研究进展[J].天津药学,2001,13(3):18-20.
[39] 周韶华, 肖小河, 袁海龙,等. 新型给药系统及其在中药制剂中的研究进展[J]. 中国中药杂志, 2003,28(7):589-592.
[40] 叶咏年. 透皮给药近况选述[J]. 天津药学, 2001,13(3):1-3.
[41] 昝佳,蒋国强,陈军.经皮给药系统的研究进展和发展趋势[J].精细化工,2002,19(63):18-20.
[42] 黄复生,贺俊英.脂质体经皮给药研究进展[J].中国现代应用药学杂志,2002,19(6):460-463.
[43] 胡晋红,张立超,朱全刚.我国透皮给药的研究进展[J].解放军药学学报,2002,18(1):38-41.
[44] 曹琴,丁志建,丁雪鹰.非甾体抗炎药透皮给药的研究进展[J].药学实践杂志,2003,21(3):147-149.
[45] 胡新, 焦元元, 陈旭, 等. 有序排列的类脂双层膜外构筑、稳定性与经皮促渗关系[J]. 中南药学,2004,2(2):67-69.
[46] 陈浩凡, 成志毅, 王锦贤. 促进经皮给药方法的研究进展[J]. 广东药学.2000,10(2):1-5.
[47] 张仲源, 徐莉. 透皮药物体内吸收的另一条途径[J]. 中医外治杂志, 2005,14(1):8-9.
[48] 许景峰, 赵维娟, 张梅等. 100 种药物透皮吸收行为的试验研究及经验回归方程的推论[J]. 中国药学杂志.1998,33(2):86-91.
[49] Sui Yi, Nie Zan. Trans-meridional-point therapeutucs and transdermal therapeutic system[J]. Chinesejournal of clinical rehabilitation, 2005,9(7):210-211.
[50] 刘未艾, 叶德宝. 穴位贴敷疗法透皮给药的研究进展[J]. 中医药通报, 2004,3(4):59-62.
[51] 刘祖舜, 周爱玲, 丁裴. 等. 腧穴对药物化学性刺激的反应[J]. 上海针灸杂志, 1996,15(5):33-34.
[52] 董洪涛, 李静. 经络穴位经皮给药系统的机理研究[J]. 甘肃中医, 1999,12(5):58-59.
[53] Singh P,Boniello S,Liu P,et al.transdermal Iontophoretic delivery of methylphenidate HCl in vivo[J].Int J Pharm,1999,178(1):121-128.
[54] Stamatialis DF,Rolevink HM,Koops GH.Delivery of timolol through artificial membranes and pig stratum comeum[J],J Pharm Sci,2003,92(5):1037-1039.
[55] 王浩,侯惠民.电致孔对离体裸鼠皮肤屏障性质的影响[J].中国医院药学杂志,2002,33(3):124-126.
[56] 潘研 , 赵会英 , 郑俊民 . 电致孔和离子导入对胰岛素经皮渗透的促进作用 [J]. 药学学报,2002,37(8):649-652.
[57] 俞媛.盐酸哌甲酯经皮渗透特性及其透皮给药系统的研究[D].上海: 第二军医大学,2004.
[58] Touitou E,Godin B,Weiss C.Enhanced delivery og drugs into and across the skin by ethosomal[J].Drug Dev Res,2000,50(3/4):406-415.
[59] Touitou E,Dayan N, Bergelsion L,et al.Ethosomea-novel vesicular carriera for enhanced delivery:characterization and skin penetration properties[J].J Controlled Release,2000, 65(3):403-418.
[60] Touitou E,Dodin N,et al.Intracellular delivery mediated by an ethosomal carrier[J]. Biomaterials,2001,22(22):3053-3059.
[61] Fang JY,Hong CT,Chiu WT,et al.Effect of liposomes and niosomes on skin permeation of enoxacin[J].Int J Pharm, 2001,219 (1-2):61-72.
[62] Fang JY,Yu SY,Wu PC,et al.In vitro skin permeation of estradiol from various proniosome formulation[J].Int J Pharm,2001,215(1-2):91-99.
[63] Gevc G,Blume G,New,highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, transfersomes[J].Biochim Biophys Acta,2001,1514(2):191-205.
[64] Guo J,Ping Q,Sun G,et al.Lecithin vesicular carriers for transdermal delivery of cyclosporine A[J].int J Pharm,2000,194(2):201-207.
[65] Wu H,Ramachandran C,Weiner ND,et al.Topical trandport of hydrophilic compounds using water-in-oil nanoemulsions[J],Int J Pharm,2001,220(1~2):63-75.
[66] Youenang P,Martin P,de luca M,et al.Transdermal delivery of glucose through hairless rat skin in vitro: effect of multiple and simple emulsions[J].Int J Pharm,1998,171(2):207-215.
[67] Alvarez-Figueroa MJ,Blanco-Mendez J.Transdermal delivery of methotrexate: iontophor- etic delivery from hydrogels and passive delivery from microemulsions[J].Int J Pharm.2001,215(1):57-65.
[68] 朱晓亮,陈志良,曾抗.微乳透皮给药系统的研究现状及展望[J].广东医学,2005,26(4):563-564.
[69] 王晓黎,蒋雪涛.微乳在药剂学上的应用[J].解放军药学学报, 2000,16(2):88-91.
[70]吴顺,李三鸣,赵国斌.微乳及其在药剂学中的应用[J].沈阳药科大学学报,2003,20(5):381-3 85.
[71] Peltola S, Saarinen-savolainen P, Kiesvaara J, et al. Microemulsion for topical delivery of estradiol[J]. Int J Pharm, 2003, 254(2):99-107 .
[72] Kreilgaard M, Pedersen E J, Jaroszewski J W. NMR characterization and transdermar drug delivery potential of microemusion systems[J]. J Control Release, 2000,69(3):421-433.
[73] Wu H W, Ramachandran C, Weiner N D,et al. Topical transport of hydrophilic compounds usingwater-in-oil nanoemulsion[J]. Int J Pharm, 2001,220(1-2):63-75.
[74] Changez M, Varshney M. Aerosol-OT microemulsions as transdermal carriers of tetracaine hydrochloride[J].Drug Dev Ind Pharm, 2000,26(5):507-512.
[75] Cechel GC, Maffei P, Moretti MD, et al. In vitro permeation through porcine buccal mucosa of Salvia desoleana Atzei & Pici essential oil from topical formulation[J].Int J Pharm, 2000,195(1-2):171-177.
[76] Luo Xingping, Zhai Zongde, Zhao Yanfang. Microemulsion electrolinetic chromatographic determination of bufadienolides in toad venom and in traditional Chinese medicine[J]. Anal Bioanal Che m ,2006, 384:1254-1258.
[77] 王丽君,姜晓冬,高霞.雷公藤多甙片的不良反应[J].基层中药杂志.1998,12(4):52-54.
[78] 秦万章.雷公藤抗炎免疫药理[C].第四次全国雷公藤学术会议论文汇编.上海:2004.5:75-80.
[79] 力弘,贾永锋,李端.雷公藤多甙的抗炎和免疫抑制作用[J].上海医科大学学报, 2000,27(6):502-505.
[80] 周朝晖,何守志.雷公藤多甙对人工晶状体表面纤维蛋白膜形成的影响[J].眼科研究,1999,17 (3):177-179.
[81] 张永健,苏素文,谢彦华等.雷公藤多甙的抗炎作用和 NO 的关系[J].中国药学杂志,2000,35(1):20-23.
[82] 丁 育 民 , 张 茂 榉 . 雷 公 藤 多 甙 治 疗 结 缔 组 织 疾 病 的 临 床 研 究 [J]. 甘 肃 中 医 学 院 学报.1998,15(2):21-24.
[83] 张曼华.雷公藤多甙长期间隙治疗类风湿性关节炎 38 例疗效分析[J].苏州医学院学报,1994,14(4):321-322.
[84] 刘晓辉.雷公藤及其制剂治疗类风湿性关节炎的研究进展[G].第四次全国雷公藤学术会议论文汇编 2004.5 上海 98-103.
[85] 刘健,韩明向,张皖东等.新风胶囊对佐剂性关节炎大鼠血清 IL-1、TNF-α、IL-4 和 IL-10 的影响[J].安徽中医学院学报,2002,21(2):44-46.
[86] 于秋艳,张海鹏,包娜仁.雷公藤多甙对 αGVHD 小鼠 T 细胞及相关细胞因子的影响[J].中国病理生理杂志,2001(8):754.
[87] 傅建斌,梁遂兴,任利群等.雷公藤多甙对类风湿性关节炎患者血浆 TNF-α 水平影响的研究[J].中医正骨.2001,13(9):13-14.
[88] 薛建敏,徐永健,张珍祥等.雷公藤内酯醇对致敏大鼠淋巴细胞凋亡的影响[J].中华微生物和免疫学杂志,2001(2):130-133.
[89] 鲍一笑,张璐定,李莉等.雷公藤红素对 HMC-1 细胞凋亡相关基因表达的影响[J].第二军医大学学报,2001,(9):833-835.
[90] 刘健,张皖东,陈光亮等.新风胶囊对佐剂性关节炎大鼠疗效及滑膜 fas、fasL 及 bcl-2 表达的影响[J].中国中西医结合杂志,2002,22(8):599-602.
[91] 王国春 , 吴东海 . 雷公藤对类风湿性关节炎患者淋巴细胞亚群的影响 [J]. 中华内科杂志,1994(1):41-42.
[92] 要庆平,张乃峥.雷公藤单体 T4 对类风湿性关节炎患者及正常人外周血单个核细胞增殖的影响[J].中国医学科学院学报,1994(5):352-355.
[93] 高锦团 . 雷公藤多甙治疗激素依赖型阿司匹林性哮喘 36 例 [J]. 中国中西医结合杂志.199414(12):727-729.
[94] 戴小欣.雷公藤在临床的运用及研究进展[J].湖南中医学院学报,1994(4):58-60.
[95] 訾晓梅,刘青云,彭代银,等.雷公藤贴膏抗炎镇痛作用的实验研究[J].中药新药与临床药理,2001(5):345-347.
[96]杨俊伟,戴春笋,陈朝红,等,雷公藤内酯醇对 T 细胞功能的影响与 Camp/PKA 的关系[J].肾脏病与透析肾移植杂志,1998, 7 (2):106-113.
[97]Yang Y L, Liu Z H, Tolosa E, et al, Triptolide induces apoptotic death of T lymphocyte[J]. Immunopharmacol, 1998, 40:139-149.
[98] Li, Xiao-Yu, Immunomodulating components from Chinese medicines[J], Pharm aceutical biology, (Lisse, Netherlands), 2000. 38(Suppl.)33-40.
[99]董兴刚,史继学.雷公藤多试对肾性蛋自尿患者外周血单个核细胞作用的研究[J].山东医科大学学报,1999,37 (3):207-208.
[100]虞海燕,秦万章,吴厚生.雷公藤治疗系统性红斑狼疮免疫机制的研究[J].中国现代应用药学杂志,1999 ,16(2):10-13.
[101] 王振刚,王芳.雷公藤多甙诱导类风湿关节炎患者外周血单个核细胞的凋亡[J].中华风湿病学杂志,2001,5(5):325-326.
[102] Utz pj, Anderson P, Posttranslational Protein modification, apoptosis, and the bypass of tolerance to autoantigen[J].Arthritis Rheum,1998, 41:1152-1160.
[103] Lin KX, Wang CZ, Qian GS, et al, T Wilfordii hook F. inhibits expressions of IL-5 and GM-CSF by suppression activator protein-1 activites[J].Chin J Im munol, 2000,15:325-328.
[104] 朱学军,刘志红.雷公藤内酯醇对人树突状细胞体外发育及免疫学功能的影响[J].肾脏病与透析肾移植杂志,2001,10(3):217-222.
[105] 王胜军,姚笙,谢芳艺等.雷公藤多甙和白细胞介素-10 对人树突状细胞表面人类白细胞抗原-DR和 CD80 表达及白细胞介素-12p40 转录和分泌的影响[J].南京医科大学学报,2001, 21 (1):1-5.
[106] 王长征,王春霞,金远林等.哮喘豚鼠 IL-5、IL-3、GM-CSF mRNA 表达及雷公藤内酯的影响[J].中华微生物和免疫学杂志,1998,18 (2):145-148.
[107] 赖克方,王长征,郭小明等.雷公藤甲素抑制 IL-5 介导的人嗜酸性粒细胞存活延长作用及其机制研究[J].中国免疫学杂志,2000,16(11):601-603, 606.
[108] 王长征,王金平,周泽云等.雷公藤多甙治疗慢性重度哮喘的临床观察[J].实用肺科杂志,1998, 5 (1):17.
[109] 刘浩,刘志红.雷公藤内酯醇对 T 淋巴细胞核因子-κB 及其抑制分子的影响[J].南京大学学报:自科版,2000,36(5):603-609.
[110] 王军,王鹏志.CD23 在小鼠小肠移植排斥反应中作用的研究[J].天津医药.1999, 27(12):739-741.
[111] 张兴义,孙梅,王荣有.雷公藤多甙对家兔移植心脏免疫损伤性冠状动脉硬化的影响[J].白求恩医科大学学报,2000,26(1):13-14.
[112]张业伟,钱海鑫,薛换洲等.雷公藤多甙在器官移植中的应用机制 [J].中国中西医结合外科杂志,2005,11 (1):86 -88.
[113]罗佳波,李吉来,贺丰等.雷公藤在移植免疫中的研究与应用概况[J].中国中医基础医学杂志,2000,6 (2):59 -63.
[114] 高小平,李伯刚,周建等.雷公藤内酯醇体外抗肿瘤作用和诱导细胞凋亡的研究[J].天然产物研究与开发,2000,12(1):18-21.
[115] Jiang, Xiao-IIua, Wong, Benjamin Chun-Yu, et al, Functional p53 is required for triptolide-induced apotosis and AP-1 and nuclear factor-κB activation in gastric cancer cells[J]. Oncogene, 20(55):8009-8018.
[116] 周幽心,黄煌伦,许期年等.雷公藤单体体外抑制胶质瘤细胞的实验研究[J].癌症杂志,2002, 21(10):1106-1108.
[117] Lee KY, Chang W, Qiu D, et al, PG490(triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells[J].Journal of Biology Chemistry, 1999,274(19):13451-13455.
[118] 夏焱,段宏泉,张铁军,等. 雷公藤属药用植物研究进展[J].中草药.2005,36(7):1093-1096.
[119] 马文领, 刘卫.雷公藤及铅,镉对小鼠睾丸间质细胞一氧化氮合酶活性的影响[J].解剖学报.2000,31(2):183-185.
[120] 王岚, 刘惟二. 雷公藤内酯酮的雄性抗生育作用及其作用机制[J].中国医学科学院学报.2000,22(3):224-226.
[121] 夏焱.雷公藤有效成分的含量测定及色谱指纹图谱研究[D]. 天津:天津大学,2005.
[122] 韦登明,黄光照.雷公藤及其单体的药理和毒理病理学研究进展[J].中药材.2003,26 (12):894-897.
[123] 吴达荣, 安爱君, 邓有顺. 雷公藤临床应用的不良反应[J].吉林中医药, 1995,(1):40.
[124] 钱叶勇, 石炳毅, 梁春泉, 等. 雷公藤多甙对肾移植受体生殖器官的影响作用[J],中华泌尿外科杂志,2002,23(4):209-211.
[125] 邵军. 雷公藤多甙片的不良反应[J]. 医药导报. 1996,15(1):41-42.
[126] 周玉芬 , 顾正平 , 浦海英 . 雷公藤多甙片致急性肝功能损伤 1 例 [J]. 中国临床药学杂志,2002(11):5,301.
[127] 李宏,仲跻明,周海洋等.雷公藤多甙治疗肾小球疾病不良反应观察[J].药物不良反应杂志,2000,1:25-27.
[128] 范兴忠,陈勇,李新东.雷公藤在免疫性疾病治疗中副作用的观察[J].中国中西医结合肾病杂志.2001,2(2):83-85.
[129] 刘玉凤,邓惠英.雷公藤多甙致肝损伤的临床报道[J].中医药研究.1997,13(5):20.
[130] 田键,佘振钰,周孝瑚等.雷公藤多甙对大鼠生精细胞及其酶活性的影响[J].生殖与避孕,1993,13(2):127.
[131] 唐永, 张霞, 苏蓓蓓. 雷公藤在皮肤科应用中的不良反应[J]. 临床皮肤科杂志, 1998,27(6):377.
[132] 张维真, 王淑华. 雷公藤、瘤可宁对肾病患儿性腺功能的远期影响[J].中国中西医结合杂志. 1996,16(2):113.
[133] 舒尚义.口服昆明山海棠引起闭经 42 例临床观察[J].昆明医学院学报,1980,3:38.
[134] 丁艳蕊. 雷公藤毒副反应概述[J],中医药研究. 1994,(3):60.
[135] 朱天忠, 几种具有肾毒性的中药[J]. 中华肾脏病杂志,1991,7(3):190.
[136] 黄煌. 雷公藤中毒 31 例临床分析[J]. 中华内科杂志,1982,(6):363.
[137] 王淑芬,刘玉春. 雷公藤肾毒性的临床观察[J].中国中药杂志,1996,21(1):52-54.
[138] 郝向春,口服雷公藤多甙片出现多形性红斑药疹 1 例[J].中国中药杂志,1993,18(3):182.
[139] 曹建国,阮学东.雷公藤多甙片致结节性红斑 1 例[J].中国中药杂志,1994,19(12):759. [140」傅明建, 王月华, 张宝样. 雷公藤糖浆引起皮肤变应性血管炎 1 例[J].临床皮肤科杂志.1993, 22(1):52.
[141] 梅淑艳.长期应用雷公藤治疗类风湿关节炎的不良反应[J].佳木斯医学院学报,1997,20(5): 72.
[142] 巫明植. 雷公藤中毒致心律失常 1 例[J].黑龙江中医药,1994,(5):44.
[143] 陈林囡,蔡辉,于德勇. 雷公藤中毒 10 例临床分析[J].江苏医学,1987,13(2):667.
[144] 邓楚宽,雷公藤致心律失常和心电图改变的临床分析[J].中西医结合杂志,1989,(6):337.
[145] 陆晓和,陈巧云,钟荷娣,等.雷公藤多甙片致急性粒细胞减少症 9 例[J].中国医院药学杂志,1993,13(12):55.
[146] 顾克显,郑家润.雷公藤的药理及毒理研究[J].江苏医药.1987,(12):644.
[147] 陆晓如.雷公藤多甙片致急性粒细胞减少症 9 例[J].中国医院药学杂志,1993,13(2):559.
[148] 吕鹏. 雷公藤中毒原因探讨[J].天津药学,2001,13(6):49-50.
[149] 沈子龙,谢启昆. 雷公藤巴布剂透皮吸收研究[J].中国药科大学学报.1994,25(3):141-144.
[150] 季晖 , 孙备 . 雷公藤巴布剂 对大鼠佐 剂 性关节 炎 的治疗 作 用 [J]. 中 国药科大学 学报.1995,26(4):223-225.
[151] 李瑞林. 雷公藤临床安全合理运用经验[J].中国中西医结合杂志,2002,22(8):567-568.
[152] 戴寿荣,靳晓青,沈越等.滴丸剂对雷公藤减毒增效的试验研究[J],现代中药研究与实践,2003,17(5):32~33.
[153] 国家药典委员会,中华人民共和国 药典 2000 版,北京:中国医药科技出版社,2000.
[154] 部颁中药 17 册 WB3-B-3350-98,雷公藤多甙片质量标准.
[155] 阙慧卿,邓思珊,林绥.雷公藤内酯甲含量测定方法的改进[J].中药材.2005,28(2):144-145.
[156] 谢谊,王实强,刘可柔.反相高效液相色谱法测定雷公藤多甙片中雷公藤酯甲的含量研究[J].湖南中医杂志.2007,23(1):79~80.
[157] 林启寿.中草药化学成分[M].北京:科学出版社,1977.390.
[158] 刘法千,鲍立曾,熊仕强. HPLC 法测定雷公藤多苷中雷公藤内酯甲的含量[J].中国药品标准,2007,8(4):38-40.
[159] 吴晓辉,刘玉玲.微乳作为经皮给药载体的研究进展[J].中国药学杂志. 2006,41(22):1680-1685.
[160] Rong G, Genping S, Weili Y. Enhancing stability of vitamin C in CTAB/n-C5H10OH/H2O system[J]. Chem J Chinese Univer,1997,18(4): 600-604.
[161] Qian W, Hongmei D, Meiyuan ZH. Studies on diagrams of microemusion[J]. Northwest Pharmaceu, 1997,12(2):72-73.
[162] 郭宏.奥沙普秦透皮给药系统的设计与评价[D].辽宁沈阳:沈阳药科大学,2007.
[163] 曹发昊.苦参碱微乳的研究[D].陕西杨凌:西北农林科技大学,2007.
[164] 吴顺芹.氟比洛芬微乳制剂的研究[D].辽宁沈阳: 沈阳药科大学,2004.
[165] 寇贺红.丁香酚纳米乳的研制[D].陕西杨凌:西北农林科技大学,2006.
[166] 朱盛山.药物新剂型[M].北京:化学工业出版社,2003.
[167] Schechter R S. Microemulsion and Related Systems[M].New York: Marcel Dekker,1998,1-200.
[168] 于爱华.葛根素口服微乳制剂的研究[D].山东济南:山东大学,2006.
[169] 杨惊宇.隐丹参酮微乳的制备工艺及相对生物利用度的测定[D].湖南: 湖南中医学院,2005.
[170] 李华.长春西汀透皮给药系统的设计与评价[D].辽宁沈阳:沈阳药科大学,2004.
[171] GB15193.3-94 食品安全性毒理学评价程序与方法.
[172] Cao Z S,Lu F Q, Microemulsion and their apphcation for thednlgs[J].World Pharmacy,1993,14(5):289-293.
[173] 王刚,傅经国,王玉东等.O/W 型微乳的制备及其对皮肤刺激性的检测[J].日用化学工业.2006,36(5):287-290.
[174] 周力国.药物毒理学[M].北京:中国医药科技出版社,2001.9.
[175] 张学梅,廉莲.复方雷公藤多甙的毒性研究[J].辽宁中医杂志.2005,32(7):719-720.
[176] 彭勃,苗明三,王宇亮. 雷公藤多甙片致小鼠急性肝损伤的初步探讨[J]. 中国中药杂志.2003,28(11):1067~1070.
[177] 刘玉凤,邓惠英.雷公藤多甙致肝损伤的临床报道[J].中医药研究.1997,13(5):20.
[178] 李龙. 雷公藤及昆明山海棠引起的肾损害[J].中国临床医生.2006,34(12):9-10.
[179] Lawrence M. J, Drees G. Microemulsion-based media as novel drug delivery systems[J]. Advanced Drug Delivery Reviews, 2000,45(1): 89-121.
[180] 陈华兵,翁 婷, 常雪灵, 等.布洛芬微乳的制备及其透皮吸收研究[J]. 中国药学杂志,2004, 39(1): 43-45.
[181] 宋金春 , 王玉广 . 马钱子碱微乳的制备及其体外透皮吸收的研究 [J]. 中国药学杂志 , 2006,41(12):928-931.
[182] 廉云飞.吲哚美辛微乳经皮制剂的研究[D].南京:中国药科大学,2004.
[183] Mei Z N, Li X K, Wu Q R, et al. The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle[J].Pharmacological research,2005,5 1 :345-351.
[184] 贾公孚, 李涛, 许莉. 药物毒副反应防治手册[M]. 北京:中国协和医科大学出版社, 2004.
[185] 孙红武, 欧阳五庆.盐酸黄连素纳米微乳的研制及其体外抗菌活性研究[J]. 西北农林科技大学学报:自然科学版, 2007,35(1):54-57.
[186] 杨惊宇, 严 冬,罗杰英, 等. 新型药物剂型—微乳[J].中国医学工程.2005,13(4):378-381.
[187] 高 岚, 张仲一, 张莉,等. 薏苡仁汤镇痛消炎作用试验研究[J].天津中医学院学报,2005, 24(1):17-19.
[188] 陈奇主编.中药药理研究方法学[M].北京:人民卫生出版社,1993: 305-307.
[189] 杜冠华,李学军,张永祥,等.药理学实验指南一新药发现和药理学评价[M].北京:科学出版社,2001:529-539.
[190] 章灵华. 丹皮酚抗炎免疫调节作用及其机制[D]. 北京: 中国协和医科大学,1995.
[191] 肖 诚, 何颖辉, 黄芳华,等. 雷公藤多甙对佐剂性关节炎大鼠自由基和炎症因子的影响[J].北京中医药大学学报,2006,29(6):389-392.
[192] 赵 宁, 周 静,肖 诚,等.雷公藤多甙对大鼠佐剂性关节炎黏膜免疫的影响[J].中国中医药信息杂志,2005,12(10):32-33.
[193] 于海荣.目穿山龙总皂甙对大鼠淋巴细胞功能影响的血清药理学研究[D].石家庄:河北药科大学,2004.
[194] 徐红丽,郭婷婷,傅 莉,等.5 种海洋动物多糖对体外小鼠脾淋巴细胞及大鼠睾丸支持细胞增殖作用的比较[J].中国药学杂志, 2006,41(11):839-841.
[195] 邓兆智,林院昌,欧润妹,等.复方雷公藤涂膜剂治疗活动期类风湿关节炎的临床再观察[J].广州中医药大学学报,1998,15,(3):180.
[196] Yu L, Wu S L, Zhang M, et al. Effect of resveratrol alone and its combination with cyclosporine A on the immune function of human peripheral blood Tlymphocytes[J]. Chin J Cell Mol Immunol, 2003,19(6): 549-551.
[197] Anna K, Nissim G. Microemulsions as transdermal drug delivery vehicle[J]. Advances and Interface Science.2006,123-126:369-385.
[198] Rhee Y S, Choi J G, Chi S C, et al. Transdermal delivery of ketoprofen using microemusions[J]. Int J Pharm, 2001,228:161.
[199] 陈纪藩,刘清平,陈光星,等通痹灵对胶原诱导性关节炎大鼠滑膜组织血管内皮生长因子表达水平的影响汇[J].广州中医药大学学报.2003,20(1):4.
[200] 马东来,李俊,陈敏珠.大鼠佐剂型关节炎的诱导激起免疫异常研究[J].中国实验临床免疫学杂志.1995,7(3):1.
[201] 黄世峰,肖长虹,顾为望,等. 兔关节滑膜细胞的分离、培养和纯化[J].中国人兽共患病学报,2006,22(11):1045-1047.
[202] 王斌,陈敏珠,徐叔云.大鼠滑膜细胞的分离和培养[J].中国药理学通报,1994,10(2):73-74.
[203] 唐玲丽, 高洁生, 陈新瑞. 白藜芦醇体外诱导类风湿性关节炎滑膜细胞凋亡的实验研究[J]. 中南药学. 2006,4(4):245-248.
[204] 曾润铭,刘梦璋,林菁.四种常用抗类风湿性药物对成纤维样滑膜细胞体外增殖的影响[J].2005,9(10):67-69.
[205] 窦建卫,雷 莹,王嗣岑. 雷公藤毒性的研究现状[J].陕西中医.2006,27(4):485-487.
[206] 王丽君,姜晓冬.雷公藤多甙片的不良反应[J].基层中药杂志.1998,12(4):52-54.
[207] Kawagoshi Y ,Tsukagoshi Y, Fukunaga L. Determination of estrogenic activity in la ndfill leachate by simplified yeast two-hybrid assay.J Environ Monit.2002,4(6):1040-1046.
[208] 周光伟,沈权,金若钰,等.雷公藤多甙对类风湿性关节炎患者滑膜细胞凋亡的影响[J].浙江临床医学.2007,9(8):1034-1035.
[209] 刘峰,董红宇,董丽华,等. 雷公藤多甙诱导类风湿性关节炎滑膜细胞凋亡的研究[J].吉林医学,2005,26(4):356-357.
[210] 刘玉凤,邓惠英.雷公藤多甙致肝损伤的临床报道[J].中医药研究.1997,13(5):163.
[211] 陈勇, 程明, 刘春霞.肝脏毒性中药的研究现状与展望[J].中草药,2004,35(11):1315-1317.
[212] 李龙.雷公藤及昆明山海棠引起的肾损害[J].中国临床医生.2006,34(12):9-10.
[213] 顾光. 肝、肾毒性体外筛选方法的建立及其在保健食品原料毒性筛选上的应用[D]. 北京: 中国疾病预防控制中心, 2005.
[214] Kawagoshi Y, Tsukagoshi Y, Fukunaga I. Determination of estrogenic activity in landfill leachate by simplified yeast two-hybrid assay. J Environ Monit, 2002,4(6): 1040-1046.
[215] 陈新谦, 金有豫. 新编药物学[M]. 北京:人民卫生出版社. 1975.
[216] 孙洪武.黄连素纳米乳给药系统的研究[D].陕西杨凌:西北农林科技大学,2007.
[217] 聂侃,安伟健,夏光成.不同产地雷公藤属植物根中有效成分含量的比较[J].中草药.199425, (10):539-541.
[218] 中国药典委员会. 中国药典[M]. 北京,2005.
[219] 朱全刚,胡晋红,奚炜,等.酮洛芬前体药物皮肤渗透代谢的立体选择性研究[J].中国药科大学学报.2005,36(1):18-21.
[220] 潘卫三.新药制剂技术[M].北京:化学工业出版社.2004.
[221] 徐叔云,陈修,卞如濂.临床药理学(上)[M].上海:上海科学技术出版社,1983.
[222] 王广基.药物代谢动力学[M].北京:化学工业出版社,2005.
[223] 刘昌孝.实用药物动力学[M].天津:中国医药科技出版社,2003.
[224] 魏树礼.生物药剂学与药物动力学[M]. 北京:中国协和医科大学联合出版社.1997.
[225] 杨惊宇.隐丹参酮微乳的制备工艺及相对生物利用度的测定[D].湖南长沙:湖南中医学院,2005.
[226] 李佩芬,李巧云,李瑞.雷公藤多甙的表观动力学参数测定[J].中药药理与临床.1994(1):29-31.